Index to Financial Statements

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2012

orApril 30, 2013

OR
¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period fromto

Commission File Number: 0-28132

STREAMLINE HEALTH SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware
31-1455414

(State or other jurisdiction of

incorporation or organization)


(I.R.S. Employer

Identification No.)


1230 Peachtree St.Street, NE, Suite 1000,

Atlanta, GA 30309

(Address of principal executive offices) (Zip Code)

(404)-446-0050

446-0050

(Registrant’s telephone number, including area code)



Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer¨

¨
Accelerated filer¨

¨
Non-accelerated filer¨

¨
Smaller reporting companyx
x(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ¨        No x

Number


The number of shares outstanding of the Registrant’s Common Stock, ($.01$.01 par value, per share) issued and outstanding, as of DecemberJune 14, 2012: 12,639,988.


TABLE OF CONTENTS2013: 12,964,809

 Page



Part I.

FINANCIAL INFORMATION

Item 1.

TABLE OF CONTENTS
 

Page

Part I.FINANCIAL INFORMATION
Item 1.Financial Statements
Condensed Consolidated Balance Sheets at October 31, 2012April 30, 2013 and January 31, 20122013
 3

Condensed Consolidated Statements of Operations for the three and nine months ended October 31,April 30, 2013 and 2012 and 2011

 5

Condensed Consolidated Statement of Changes in Stockholders’ Equity for the Period from February 1, 2012 to October 31, 2012

6

Condensed Consolidated Statements of Cash Flows for the ninethree months ended October 31,April 30, 2013 and 2012 and 2011

 7

Notes to Condensed Consolidated Financial Statements

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3.Quantitative and Qualitative Disclosures About Market Risk17
Item 4.Controls and Procedures
Part II.OTHER INFORMATION 
Item 1.Legal Proceedings

Item 4.

6.
Exhibits
 

Controls and Procedures

Signatures
24





PART I. FINANCIAL INFORMATION

Part II.

OTHER INFORMATION

Item 1.

Legal Proceedings

25

Item 6.

Exhibits

25

Signatures

26

PART I. FINANCIAL INFORMATION

Item 1.CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

Assets

   (Unaudited)
October 31,  2012
  January 31, 2012 

Current assets:

   

Cash and cash equivalents

  $10,528,695   $2,243,054  

Accounts receivable, net of allowance for doubtful accounts of $134,000 and $100,000, respectively

   3,389,738    4,484,605  

Contract receivables

   648,736    430,370  

Prepaid hardware and third party software for future delivery

   22,777    38,193  

Prepaid client maintenance contracts

   1,038,035    788,917  

Prepaid and other assets

   555,310    256,104  

Deferred income taxes

   —      167,000  
  

 

 

  

 

 

 

Total current assets

   16,183,291    8,408,243  
  

 

 

  

 

 

 

Non-current assets:

   

Property and equipment:

   

Computer equipment

   3,418,500    2,892,885  

Computer software

   2,196,236    2,131,730  

Office furniture, fixtures and equipment

   818,231    756,375  

Leasehold improvements

   693,890    667,000  
  

 

 

  

 

 

 
   7,126,857    6,447,990  

Accumulated depreciation and amortization

   (5,778,675  (5,232,321
  

 

 

  

 

 

 

Property and equipment, net

   1,348,182    1,215,669  
  

 

 

  

 

 

 

Contract receivables, less current portion

   142,021    221,596  

Capitalized software development costs, net of accumulated amortization of $16,733,274 and $14,805,236, respectively

   13,119,354    9,830,175  

Intangible assets, net

   8,517,084    417,666  

Deferred financing cost, net

   1,211,912    145,857  

Goodwill

   12,038,226    4,060,504  

Other, including deferred income taxes of $0 and $711,000, respectively

   366,857    841,348  
  

 

 

  

 

 

 

Total non-current assets

   36,743,636    16,732,815  
  

 

 

  

 

 

 
  $52,926,927   $25,141,058  
  

 

 

  

 

 

 

(Unaudited)
    
 April 30, 2013 January 31, 2013
ASSETS   
Current assets:   
Cash and cash equivalents$4,001,223
 $7,500,256
Accounts receivable, net of allowance for doubtful accounts of $134,000 and $134,000, respectively9,591,294
 8,685,017
Contract receivables558,762
 1,481,819
Prepaid hardware and third party software for future delivery24,448
 22,777
Prepaid client maintenance contracts1,525,261
 1,080,330
Other prepaid assets810,321
 997,024
Other current assets241,105
 110,555
Total current assets16,752,414
 19,877,778
Non-current assets:   
Property and equipment:   
Computer equipment3,467,545
 3,420,452
Computer software2,200,854
 2,196,236
Office furniture, fixtures and equipment870,079
 843,274
Leasehold improvements697,570
 697,570
 7,236,048
 7,157,532
Accumulated depreciation and amortization(6,130,170) (5,958,727)
Property and equipment, net1,105,878
 1,198,805
Contract receivables, less current portion104,526
 126,626
Capitalized software development costs, net of accumulated amortization of $18,159,290 and $17,464,601, respectively12,581,974
 12,816,486
Intangible assets, net7,873,643
 8,188,131
Deferred financing costs, net417,816
 541,740
Goodwill12,152,883
 12,133,304
Other438,951
 383,708
Total non-current assets34,675,671
 35,388,800
 $51,428,085
 $55,266,578

See Notesaccompanying notes.


2

Index to Condensed Consolidated Financial Statements

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

Liabilities and Stockholders’ Equity

   (Unaudited)
October 31,  2012
  January 31, 2012 

Current liabilities:

   

Accounts payable

  $832,657   $879,027  

Accrued compensation

   1,603,355    887,130  

Accrued other expenses

   1,373,307    479,526  

Deferred revenues

   6,262,960    6,496,938  

Contingent consideration for earn-out

   1,319,559    —    

Current portion of long term debt

   1,250,000    —    
  

 

 

  

 

 

 

Total current liabilities

   12,641,838    8,742,621  
  

 

 

  

 

 

 

Non-current liabilities:

   

Term loans

   12,750,000    4,120,000  

Convertible notes payable, net of unamortized discount of $1,822,255 and $0, respectively

   3,877,322    3,000,000  

Warrants liability

   4,138,783    —    

Lease incentive liability

   101,453    47,193  

Contingent consideration for earn-out, less current portion

   —      1,232,720  
  

 

 

  

 

 

 

Total non-current liabilities

   20,867,558    8,399,913  
  

 

 

  

 

 

 

Total liabilities

   33,509,396    17,142,534  
  

 

 

  

 

 

 

Series A 0% Convertible Redeemable Preferred Stock, $.01 par value per share, $7,250,355 redemption value, 4,000,000 shares authorized, 2,416,785 issued and outstanding

   2,979,170    —    

Stockholders’ equity:

   

Common stock, $.01 par value per share, 25,000,000 shares authorized, and 12,582,598 and 10,433,716 shares issued and outstanding, respectively

   125,826    104,338  

Convertible Redeemable Preferred Stock, $0.01 par value per share, 1,000,000 authorized, no shares issued

   —      —    

Additional paid in capital

   44,351,334    38,360,980  

Accumulated deficit

   (28,038,799  (30,466,794
  

 

 

  

 

 

 

Total stockholders’ equity

   16,438,361    7,998,524  
  

 

 

  

 

 

 
  $52,926,927   $25,141,058  
  

 

 

  

 

 

 


 
  

April 30, 2013 January 31, 2013
LIABILITIES AND STOCKHOLDERS’ EQUITY   
Current liabilities:   
Accounts payable$794,684
 $1,495,913
Accrued compensation1,355,100
 2,088,850
Accrued other expenses1,384,160
 1,325,039
Current portion of long-term debt1,250,000
 1,250,000
Deferred revenues9,211,458
 9,810,442
Contingent consideration for earn-out1,319,559
 1,319,559
Current portion of deferred tax liability35,619
 35,619
Total current liabilities15,350,580
 17,325,422
Non-current liabilities:   
Term loans12,125,000
 12,437,501
Warrants liability4,956,000
 3,649,349
Lease incentive liability, less current portion32,015
 99,579
Deferred income tax liability, less current portion529,709
 529,709
Total non-current liabilities17,642,724
 16,716,138
Total liabilities32,993,304
 34,041,560
Series A 0% Convertible Redeemable Preferred Stock, $.01 par value per share, $11,999,985 redemption value, 4,000,000 shares authorized, 3,999,995 shares issued and outstanding, net of unamortized preferred stock discount of $4,049,980 and $4,234,269, respectively7,950,005
 7,765,716
Stockholders’ equity:   
Common stock, $.01 par value per share, 25,000,000 shares authorized; 12,680,615 and 12,643,620 shares issued and outstanding, respectively126,806
 126,436
Convertible redeemable preferred stock, $.01 par value per share, 1,000,000 shares authorized, no shares issued
 
Additional paid in capital48,913,339
 49,178,389
Accumulated deficit(38,555,369) (35,845,523)
Total stockholders’ equity10,484,776
 13,459,302
 $51,428,085
 $55,266,578

See Notesaccompanying notes.


3

Index to Condensed Consolidated Financial Statements

STREAMLINE HEALTH SOLUTIONS, INC.

CONDENSED


CONDENDSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three and Nine Months Ended October 31,

(Unaudited)

   Three Months  Nine Months 
   2012  2011  2012  2011 

Revenues:

     

Systems sales

  $290,294   $232,395   $719,495   $526,597  

Professional services

   1,089,814    833,592    3,153,672    2,708,824  

Maintenance and support

   3,148,442    2,279,886    7,797,263    6,558,484  

Software as a service

   2,005,813    966,218    5,358,120    2,804,141  
  

 

 

  

 

 

  

 

 

  

 

 

 

Total revenues

   6,534,363    4,312,091    17,028,550    12,598,046  
  

 

 

  

 

 

  

 

 

  

 

 

 

Operating expenses:

     

Cost of systems sales

   717,901    583,388    1,936,761    1,751,890  

Cost of professional services

   854,997    572,056    1,910,951    1,923,576  

Cost of maintenance and support

   918,750    513,868    2,349,745    1,651,884  

Cost of software as a service

   550,875    480,368    1,849,962    1,334,659  

Selling, general and administrative

   2,926,830    1,494,891    6,800,794    4,742,084  

Product research and development

   866,659    303,973    1,833,865    1,063,903  
  

 

 

  

 

 

  

 

 

  

 

 

 

Total operating expenses

   6,836,012    3,948,544    16,682,078    12,467,996  
  

 

 

  

 

 

  

 

 

  

 

 

 

Operating income (loss)

   (301,649  363,547    346,472    130,050  

Other income (expense):

     

Interest expense

   (895,142  (25,896  (1,494,161  (67,529

Miscellaneous income (expense)

   43,549    (36,885  55,805    (42,155
  

 

 

  

 

 

  

 

 

  

 

 

 

Earnings (loss) before income taxes

   (1,153,242  300,766    (1,091,884  20,366  

Income tax benefit (expense)

   3,552,879    (5,000  3,519,879    (12,315
  

 

 

  

 

 

  

 

 

  

 

 

 

Net earnings

  $2,399,637   $295,766   $2,427,995   $8,051  
  

 

 

  

 

 

  

 

 

  

 

 

 

Less: deemed dividends on Series A Preferred Shares

   (139,133   (139,133 
  

 

 

   

 

 

  

Net earnings attributable to common shareholders

  $2,260,504    $2,288,862   
  

 

 

   

 

 

  

Basic net earnings per common share

  $0.18   $0.03   $0.20   $0.00  
  

 

 

  

 

 

  

 

 

  

 

 

 

Number of shares used in basic per common share computation

   12,393,352    9,943,567    11,346,428    9,823,937  
  

 

 

  

 

 

  

 

 

  

 

 

 

Diluted net earnings per common share

  $0.15   $0.03   $0.18   $0.00  
  

 

 

  

 

 

  

 

 

  

 

 

 

Number of shares used in diluted per common share computation

   15,365,238    9,958,947    12,417,256    9,837,750  
  

 

 

  

 

 

  

 

 

  

 

 

 


 (Unaudited)
 Three Months Ended
 April 30, 2013 April 30, 2012
Revenues:   
Systems sales$324,646
 $353,530
Professional services919,351
 1,122,439
Maintenance and support3,380,600
 2,351,575
Software as a service1,848,741
 1,617,589
Total revenues6,473,338
 5,445,133
Operating expenses:   
Cost of systems sales638,597
 686,528
Cost of services974,462
 552,482
Cost of maintenance and support984,588
 725,281
Cost of software as a service579,080
 682,306
Selling, general and administrative3,580,867
 1,669,760
Research and development1,097,010
 456,363
Total operating expenses7,854,604
 4,772,720
Operating income (loss)(1,381,266) 672,413
Other income (expense):   
Interest expense(566,565) (207,830)
Miscellaneous income (expenses)(742,265) 36,045
Earnings (loss) before income taxes(2,690,096) 500,628
Income tax expense(19,750) (9,000)
Net earnings (loss)$(2,709,846) $491,628
Less: deemed dividends on Series A Preferred Shares$(341,637) $
Net earnings (loss) attributable to common shareholders$(3,051,483) $491,628
Basic net earnings (loss) per common share$(0.24) $0.05
Number of shares used in basic per common share computation12,534,474
 10,307,259
Diluted net earnings (loss) per common share$(0.24) $0.05
Number of shares used in diluted per common share computation12,534,474
 10,307,259

See Notesaccompanying notes.


4

Index to Condensed Consolidated Financial Statements

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN

STOCKHOLDERS’ EQUITY

   Common
stock shares
   Common
stock
   Additional
paid in
capital
  Accumulated
(deficit)
  Total
stockholders’
equity
 

Balance at February 1, 2012

   10,433,716    $104,338    $38,360,980   $(30,466,794 $7,998,524  
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

 

Stock issued to Employee Stock Purchase Plan and exercise of stock options

   88,742     887     160,920    —      161,807  

Restricted stock issued

   137,325     1,373     (1,373  —      —    

Conversion of note payable, Interpoint

   1,529,729     15,297     3,100,885    —      3,116,182  

Stock consideration for acquisition

   393,086     3,931     1,497,678    —      1,501,609  

Issuance of common stock warrants

   —       —       2,441,852    —      2,441,852  

Issuance costs

   —       —       (263,072  —      (263,072

Reclassification of common stock warrants to liability

   —       —       (4,138,783  —      (4,138,783

Beneficial conversion feature of Series A Preferred Stock

   —       —       2,685,973    —      2,685,973  

Share-based compensation expense

   —       —       645,407    —      645,407  

Deemed dividends on Series A Preferred Stock

   —       —       (139,133  —      (139,133

Net earnings

   —       —       —      2,427,995    2,427,995  
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

 

Balance at October 31, 2012

   12,582,598    $125,826    $44,351,334   $(28,038,799 $16,438,361  
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

 

STREAMLINE HEALTH SOLUTIONS, INC.


CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Nine Months Ended October 31,

(Unaudited)

       2012      2011 

Operating activities:

   

Net earnings

  $2,427,995   $8,051  

Adjustments to reconcile net earnings (loss) to net cash provided by operating activities, net of effect of acquisitions:

   

Depreciation and amortization

   2,847,665    2,008,432  

Loss on disposal of equipment

   —      26,667  

Share-based compensation expense

   645,407    529,104  

Deferred tax benefit

   (3,564,612  —    

Provision for accounts receivable

   —      40,000  

Amortization of debt discount

   111,584    —    

Fair value adjustment for contingent earnout

   86,839    —    

Net loss from conversion of convertible note

   56,682    —    

Change in assets and liabilities:

   

Accounts and contract receivables

   (1,351,935  419,517  

Other assets

   (482,785  (89,066

Accounts payable

   (137,107  161,609  

Accrued expenses

   947,630    (574,012

Deferred revenues

   881,677    (1,904,641
  

 

 

  

 

 

 

Net cash provided by operating activities

   2,469,040    625,661  
  

 

 

  

 

 

 

Investing activities:

   

Purchases of property and equipment

   (546,061  (245,262

Capitalization of software development costs

   (1,571,420  (1,970,000

Payment for acquisition

   (12,161,634  —    
  

 

 

  

 

 

 

Net cash used in investing activities

   (14,279,115  (2,215,262
  

 

 

  

 

 

 

Financing activities:

   

Net change in borrowings

   9,880,000    550,000  

Payment of deferred financing costs

   (1,246,107  —    

Proceeds from exercise of stock options and stock purchase plan

   161,823    92,711  

Proceeds from private placement

   12,000,000    —    

Payment of success fee

   (700,000  —    

Payment on capital lease obligation

   —      (156,621
  

 

 

  

 

 

 

Net cash provided by financing activities

   20,095,716    486,090  
  

 

 

  

 

 

 

Increase (decrease) in cash and cash equivalents

   8,285,641    (1,103,511

Cash and cash equivalents at beginning of period

   2,243,054    1,403,949  
  

 

 

  

 

 

 

Cash and cash equivalents at end of period

  $10,528,695   $300,438  
  

 

 

  

 

 

 

Supplemental cash flow disclosures:

   

Interest paid

  $1,181,929   $61,532  
  

 

 

  

 

 

 

Income taxes paid

  $78,041   $19,136  
  

 

 

  

 

 

 

Supplemental Disclosure of Non-Cash Financing Activity

In June 2012, the $3,000,000 convertible note and accrued interest was converted

 (Unaudited)
 Three Months Ended
 April 30, 2013 April 30, 2012
Operating activities:   
Net earnings (loss)$(2,709,846) $491,628
Adjustments to reconcile net earnings (loss) to net cash (used in) provided by operating activities:   
Depreciation171,443
 179,552
Amortization of capitalized software development costs694,689
 554,983
Amortization of intangible assets314,488
 91,196
Amortization of other deferred costs82,814
 19,688
Valuation adjustment for warrants liability645,354
 
Share-based compensation expense467,401
 178,323
Changes in assets and liabilities, net of assets acquired:   
Accounts and contract receivables38,880
 1,767,779
Other assets(414,056) (486,029)
Accounts payable(768,793) 154,110
Accrued expenses(632,741) (202,723)
Deferred revenues(598,984) (1,122,692)
Net cash (used in) provided by operating activities(2,709,351) 1,625,815
Investing activities:   
Purchases of property and equipment(78,516) (227,878)
Capitalization of software development costs(460,177) (507,000)
Net cash used in investing activities(538,693) (734,878)
Financing activities:   
Principal repayments on term loans(312,501) 
Proceeds from exercise of stock options and stock purchase plan61,512
 
Net cash used in financing activities(250,989) 
(Decrease) increase in cash and cash equivalents(3,499,033) 890,937
Cash and cash equivalents at beginning of period7,500,256
 2,243,054
Cash and cash equivalents at end of period$4,001,223
 $3,133,991


See accompanying notes.

5


NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

STATMENTS

(Unaudited)


NOTE A BASIS OF PRESENTATION

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by Streamline Health Solutions, Inc. (“we”, “us”, or “our”(the "Company"), pursuant to the rules and regulations applicable to quarterly reports on Form 10-Q of the U. S. Securities and Exchange Commission. Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of our management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. These Condensed Consolidated Financial Statements should be read in conjunction with the financial statements and notes thereto included in our most recent annual report on Form 10-K, Commission File Number 0-28132. Operating results for the three and nine months ended October 31, 2012April 30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2013.

2014.


NOTE B SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of our

The Company's significant accounting policies isare presented in “Note B – Significant Accounting Policies” in the fiscal year 20112012 Annual Report on Form 10-K. Users of financial information for interim periods are encouraged to refer to the footnotes contained in the Annual Report on Form 10-K when reviewing interim financial results.

Acquisitions

On December 7, 2011, we completed

Use of Estimates
The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the acquisition of substantially all ofamounts reported in the assets of Interpoint Partners, LLC (“Interpoint”). The net acquired assetsfinancial statements and liabilities, and related revenue and expense since December 7, 2011 are included in our condensed consolidated financial statements.

On August 16, 2012, we completed the acquisition of Meta Health Technology, Inc. (“Meta”), please see Note C for further details.

accompanying notes. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The carrying amount of the Company’s long-term debt approximates fair value since the interest rates being paid on the amounts approximate the market interest rate. Long-term debt is classified as Level 2. The fair value of contingent consideration for earn-out and warrants liability is determined by management with the assistance of an independent third party valuation specialist. The Company used a binomial model to estimate the fair value of the contingent consideration for earn-out and warrants liability. The contingent consideration for earn-out and warrants liability are classified as Level 3.

Revenue Recognition

We derive

The Company derives revenue from the sale of internally developed software either by licensing or by software as a service (SaaS)("SaaS"), through ourthe direct sales force or through third-party resellers. Clients withLicensed, locally-installed, softwareclients utilize ourthe Company’s support and maintenance services for a separate fee, whereas SaaS fees include support and maintenance. WeThe Company also derivederives revenue from professional services that support the implementation, configuration, training, and optimization of ourthe applications. Additional revenues are also derived from reselling third-party software and hardware components.

We recognizeThe Company recognizes revenue in accordance with ASC 985-605,Software-Revenue Recognitionand ASC 605-25Revenue Recognition Multiple-element arrangements. RevenueThe Company commences revenue recognition typically commences when the following criteria all have all been met:

Persuasive evidence of an arrangement exists,


6

Index to Financial Statements
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Delivery has occurred or services have been rendered,

The arrangement fees are fixed or determinable, and

Collection is considered probable.

probable

If we determinethe Company determines that any of the above criteria hashave not been met, wethe Company will defer recognition of the revenue until all the criteria have been met. Maintenance and support term license and SaaS agreements entered into are generally non-cancelable, or contain significant penalties for early cancellation, although clients typically have the right to terminate their contracts for cause if we failthe Company fails to perform material obligations. However, if non-standard acceptance periods or non-standard performance criteria, cancellation or right of refund terms are required, revenue is recognized upon the satisfaction of such criteria, as applicable.
Revenues from resellers are recognized gross of royalty payments to resellers.

Multiple Element Arrangements
Revenue Recognition – Multiple-Deliverable Revenue Arrangements

We recognize revenue in accordance withOn February 1, 2011, the Company adopted Accounting Standards Update No. 2009-13, Revenue Recognition (Topic 605), “Multiple-Deliverable“Multiple-Deliverable Revenue Arrangements — a consensus of the FASB Emerging Issues Task Force” (“ASU 2009-13”). on a prospective basis. ASU 2009-13 amendsamended the accounting standards for revenue recognition for multiple deliverable revenue arrangements to:

Provide updated guidance on how deliverables of an arrangement are separated, and how consideration is allocated;

Eliminate the residual method and require entities to allocate revenue using the relative selling price method;method and;

Require entities to allocate revenue to an arrangement using the estimated selling price (“ESP”) of deliverables if it does not have vendor specific objective evidence (“VSOE”) or third party evidence (“TPE”) of selling price.


Terms used in evaluation are as follows:

VSOE — the price at which an element is sold as a separate stand-alone transaction.

transaction

TPE — the price of an element, charged by another company that is largely interchangeable in any particular transaction.

transaction

ESP — ourthe Company’s best estimate of the selling price of an element of the transaction.

transaction

We follow

The Company follows accounting guidance for revenue recognition of multiple-element arrangements to determine whether such arrangements contain more than one unit of accounting. Multiple-element arrangements require the delivery or performance of multiple solutions, services and/or rights to use assets. To qualify as a separate unit of accounting, the delivered item must have value to the client on a stand-alone basis. Stand-alone value to a client is defined in the guidance as those that can be sold separately by any vendor or the client could resell the item on a stand-alone basis. Additionally, if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item or items must be considered probable and substantially in the control of the vendor.

We have developed

The Company has a defined pricing methodology for all elements of the arrangement and proper review of pricing to ensure adherence to ourCompany policies. Pricing decisions include cross-functional teams of senior management, which uses market conditions, expected contribution margin, size of the client’s organization, and pricing history for similar solutions when establishing the selling price.

Software as a Service

We useservice

The Company uses ESP to determine the value of SaaS arrangements because wefor a software as a service arrangement as the Company cannot establish VSOE and TPE is not a practical alternative due to differences in functionality from ourthe Company's competitors. Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution, and include calculating the equivalent value of maintenance and support on a present value basis over the term of the initial agreement period. Typically revenue recognition commences once theupon client goes livego-live on the system, and is recognized ratably over the contract term. The software portion of SaaS for our HIM (“Health Information Management”Management ("HIM") products dodoes not requireneed material modification to achieve theirits contracted function. The software portion of SaaS for our PFS (“the Company's Patient Financial Services”Services ("PFS") products require material customization and setup processes to achieve their contracted function.

System Sales

We use

The Company uses the residual method to determine fair value for a proprietary software licenselicenses sold in a multi-element arrangement. Under the residual method, the Company allocates the total value of he arrangement because we can establish fair value for all offirst to the undelivered elements. elements based on their VSOE and allocates the remainder to the proprietary software license fees.

7

Index to Financial Statements
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Typically pricing decisions for proprietary software rely on the relative size and complexity of the client purchasing the solution. Third party components are resold at prices based on a cost plus margin analysis. The proprietary software and third party components do not need any significant modification to achieve theirits intended use. When these revenues meet all criteria for revenue recognition, and are determined to be separate units of accounting, revenue is recognized. Typically this is upon shipment of components or electronic download of software. Proprietary licenses are perpetual in nature, and license fees do not include rights to version upgrades, fixes or service packs.

Term Licenses

We use ESP to determine the value of term license arrangements because we cannot establish VSOE, and TPE is not a practical alternative due to differences in functionality from our competitors. Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution. Typically revenue recognition commences once the client goes live on the system, and is recognized ratably over the contract term. The software portion of our CAC (“Computer Aided Coding”) products generally do not require material modification to achieve their contracted function.

Maintenance and Support Services

The maintenance and support components are not essential to the functionality of the software and clients renew maintenance contracts separately from software purchases at renewal rates materially similar to the initial rate charged for maintenance on the initial purchase of software. We useThe Company uses VSOE of fair value to determine fair value of maintenance and support services. Rates are set based on market rates for these types of services, and thesethe Company’s rates are comparable to rates charged by ourits competitors, which areis based on the knowledge of the marketplace by senior management. Generally, maintenance and support is calculated as a percentage of the list price of the proprietary license being purchased by a client. Clients have the option of purchasing additional annual maintenance service renewals each year for which rates are not materially different from the initial rate, but typically include a nominal rate increase based on the consumer price index. Annual maintenance and support agreements entitle clients to technology support, upgrades, bug fixes and service packs.

Term Licenses
The Company cannot establish VSOE fair value of the undelivered element in term license arrangements.  However, as the only undelivered element is post-contract customer support, the entire fee is recognized ratably over the contract term.  Typically revenue recognition commences once the client goes live on the system.  Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution. The software portion of the Company's CAC (“Computer Assisted Coding”) products generally do not require material modification to achieve their contracted function.
Professional Services

Professional services components that are not essential to the functionality of the software, from time to time, are sold separately by us.the Company. Similar services are sold by other vendors, and clients can elect to perform similar services in-house. When professional services revenues are a separate unit of accounting, revenues are recognized as the services are performed.

Professional services components that are essential to the functionality of the software, and are not considered a separate unit of accounting, are recognized in revenue ratably over the life of the client, which we approximate asapproximates the duration of the initial contract term. We deferThe Company defers the associated direct costs for salaries and benefits expense for PFS contracts. As of October 31,April 30, 2013 and 2012, we havethe Company had deferred costs of approximately $239,000.$257,000 and zero, respectively. These deferred costs will be amortized over the identical term as the associated SaaS revenues.

We use Amortization expense of these costs was approximately $45,000 and zero as of April 30, 2013 and 2012, respectively.

The Company uses VSOE of fair value based on the hourly rate charged when services are sold separately, to determine fair value of professional services. WeThe Company typically sellsells professional services on a fixed fee basis. We monitorThe Company monitors projects to assure that the expected and historical rate earned remains within a reasonable range to the established selling price.

Severances
From time to time, the Company will enter into termination agreements with associates that may include supplemental cash payments, as well as contributions to health and other benefits for a specific time period subsequent to termination. For the three months ended April 30, 2013 and 2012 , we incurred approximately $383,000 and $70,000 in severance expenses. At April 30, 2013 and January 31, 2013, the Company had accrued for $544,000 and $548,000 in severances, respectively. The Company anticipates these severances accrued at April 30, 2013 to be paid out in full by August 31, 2013.
Equity Awards
The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite vesting period. The Company incurred total annual compensation expense related to stock-based awards of $467,000 and $178,000 for the three months ended April 30, 2013 and 2012, respectively.
The fair value of the stock options granted have been estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility, and risk-free interest rate impact the fair value estimate. Further, the forfeiture rate impacts the amount of aggregate compensation. These assumptions are

8

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

subjective and are generally derived from external (such as, risk free rate of interest) and historical data (such as, volatility factor, expected term, and forfeiture rates). Future grants of equity awards accounted for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards.
The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market close price per share on the day of grant. The Company expenses the compensation cost of these awards as the restriction period lapses, which is typically a one year service period to the Company.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized.
The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. At April 30, 2013, the Company believes it has appropriately accounted for any uncertain tax positions. As part of the Meta acquisition, the Company assumed a current liability for an uncertain tax position, and expects to settle this amount in fiscal 2013. The Company has recorded $152,000 and zero of reserves for uncertain tax positions and corresponding interest and penalties as of April 30, 2013 and January 31, 2013, respectively.
Net Earnings (Loss) Per Common Share
The Company presents basic and diluted earnings per share (“EPS”) data for its common stock. Basic EPS is calculated by dividing the net income attributable to shareholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to shareholders and the weighted average number of shares of common stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, warrants and convertible preferred stock. Potential common stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A Convertible Preferred Stock are determined using the “if converted” method.

The Company's unvested restricted stock awards and Series A Convertible Preferred stock are considered participating securities under ASC 260, “Earnings Per Share”, which means the security may participate in undistributed earnings with common stock. The Company's unvested restricted stock awards are considered participating securities because they entitle holders to non-forfeitable rights to dividends or dividend equivalents during the vesting term. The holders of the Series A Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of common stock were to receive dividends, other than dividends in the form of common stock. In accordance with ASC 260, a company is required to use the two-class method when computing EPS when a company has a security that qualifies as a “participating security.” The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stock holders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding for the period. Diluted EPS for the Company's common stock is computed using the more dilutive of the two-class method or the if-converted method.

In accordance with ASC 260, securities are deemed to not be participating in losses if there is no obligation to fund such losses. For the three months ended April 30, 2013, the unvested restricted stock awards and the Series A Preferred Stock were not deemed to be participating since there was a net loss from operations. For the three months ended April 30, 2012, the effect of unvested restricted stock to the earnings per share calculation was immaterial. As of April 30, 2013, there were 3,999,995 shares of preferred stock outstanding, each share is convertible into one share of the Company's common stock. For the three months ended April 30, 2013, the Series A Convertible Preferred Stock would have an anti-dilutive effect if included in diluted EPS and therefore, was not included in the calculation. As of April 30, 2013 and January 31, 2013, there were both 137,327 unvested restricted shares of common stock outstanding. The unvested restricted shares at April 30, 2013 were excluded from the calculation as their effect would have been antidilutive.

9

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following is the calculation of the basic and diluted net earnings (loss) per share of common stock:

Three Months Ended,

April 30, 2013 April 30, 2012
Net earnings (loss)$(2,709,846) $491,628
Less: deemed dividends on Series A Preferred Stock(341,637) 
Net earnings (loss) attributable to common shareholders$(3,051,483) $491,628
Weighted average shares outstanding used in basic per common share computations12,534,474
 10,307,259
Stock options and restricted stock
 
Number of average shares used in diluted per common share computation12,534,474
 10,307,259
Basic net earnings (loss) per share of common stock$(0.24) $0.05
Diluted net earnings (loss) per share of common stock$(0.24) $0.05
Diluted (loss) earnings per share exclude the effect of 2,643,742 and 1,690,051 outstanding stock options for the three months ended April 30, 2013 and 2012, respectively. The inclusion of these shares would be anti-dilutive. For the three months ended April 30, 2013, the outstanding common stock warrants of 1,400,000 would have an anti-dilutive effect if included in diluted EPS and therefore, were not included in the calculation. There were no outstanding warrants as of April 30, 2012.
Recent Accounting Pronouncements

In February 2013, the FASB issued an accounting standard update relating to improving the reporting of reclassifications out of accumulated other comprehensive income. The update would require an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. For other amounts that are not required under GAAP to be reclassified in their entirety to net income in the same reporting period, an entity is required to cross-reference other disclosures required under GAAP that provide additional detail about those amounts. The update is effective for reporting periods beginning after December 15, 2012. This standard did not have a material effect on the Company's consolidated financial position, results of operations, or cash flows.


NOTE C ACQUISITIONS

On December 7, 2011, the Company completed the acquisition of substantially all of the assets of Interpoint Partners, LLC (“Interpoint”). This acquisition expanded the Company’s product offering into business intelligence and revenue cycle performance management. The purchase agreement also includes a contingent earn-out provision, which had an estimated value of approximately $1,320,000 and 1,320,000 at April 30, 2013 and January 31, 2013, respectively. The contingent earn-out is to be paid in cash or an additional convertible subordinated note based on the acquired Interpoint operations financial performance for the 12 month period beginning June 30, 2012 and ending June 30, 2013.
On August 16, 2012 we the Company acquired substantially all of the outstanding stock of Meta Health Technology, Inc., a New York corporation (“Meta”). WeThe Company paid a total purchase price of approximately $15,000,000,$14,790,000, consisting of cash payment of $13,400,000$13,288,000 and the issuance of 393,086 shares of ourthe Company's common stock at aan agreed upon price of $4.07$4.07 per share. The fair value of the common stock at the date of issuance was $3.82. For the three and nine month periods ending October 31, 2012, we recorded $406,000 and $957,000, respectively, of acquisition costs related to the Meta transaction, which were recorded in selling, general and administrative expense. These costs were primarily related to services provided by legal, financial, and accounting professional advisors. At October 31, 2012 we have acquired 100% of Meta’s outstanding shares.

$3.82.

The acquisition of Meta represents ourthe Company's on-going growth strategy, and is reflective of ourthe solutions development process, which is led by the needs and requirements of our clients and the marketplace in general. The Meta suite of solutions, when bundled with ourthe Company's existing solutions, will help current and prospective clients better prepare for compliance with the ICD-10 transition. As we move forward, we believeThe Company believes that the integration of our business analytics solutions with the coding solutions acquired in this transaction will position usthe Company to address the complicated issues of clinical analytics as our clients prepare for the proposed changes in commercial and governmental payment models.

The purchase price is subject to certain adjustments related principally to the delivered working capital level, which will be settled in the third quarter of fiscal 2013, and/or indemnification provisions. Under the acquisition method of accounting, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:

   Balance at August 16, 2012 

Assets purchased:

  

Cash

  $1,126,000  

Accounts receivable

   
2,300,000
  

Fixed assets

   133,000  

Other assets

   513,000  

Client relationships

   4,464,000  

Internally developed software

   3,646,000  

Trade name

   1,588,000  

Supplier agreements

   1,582,000  

Covenants not to compete

   720,000  

Goodwill(1)

   7,978,000  
  

 

 

 

Total assets purchased

  $24,050,000  
  

 

 

 

Liabilities assumed:

  

Accounts payable and Accrued liabilities

   1,164,000  

Deferred revenue obligation, net

   3,494,000  

Deferred tax liability

   4,602,000  
  

 

 

 

Net assets acquired

  $14,790,000  
  

 

 

 

Consideration:

  

Company common stock

   1,502,000  

Cash paid

   13,288,000  
  

 

 

 

Total Consideration

  $14,790,000  
  

 

 

 



10

Index to Financial Statements
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 Balance at August 16, 2012
Assets purchased: 
Cash$1,126,000
Accounts receivable2,300,000
Fixed assets133,000
Other assets513,000
Client relationships4,464,000
Internally developed software3,646,000
Trade name1,588,000
Supplier agreements1,582,000
Covenants not to compete720,000
Goodwill(1)8,073,000
Total assets purchased$24,145,000
Liabilities assumed: 
Accounts payable and Accrued liabilities1,259,000
Deferred revenue obligation, net3,494,000
Deferred tax liability4,602,000
Net assets acquired$14,790,000
Consideration: 
Company common stock1,502,000
Cash paid13,288,000
Total consideration$14,790,000
_______________
(1)Goodwill represents the excess of purchase price over the estimated fair value of net tangible and intangible assets acquired, , which is not deductible for tax purposes.

The acquired operations of Meta are consolidated with the results of the Company from August 16, 2012. Due to the new deferred tax liabilities recorded as a result of the above purchase price allocation, we were able to reduce our valuation allowance by approximately $3,600,000 representing the significant deferred tax benefit recorded in the three and nine months ended October 31, 2012.

Pro Forma Results

The operating results of Meta for the period August 16, 2012 through October 31, 2012, which include sales of $1,259,000 and net income of approximately $177,000, have been included in our consolidated financial statements.

The following unaudited pro forma information assumes the Meta acquisition occurred as of the beginning of the earliest period presented. The unaudited pro forma financial information for all periods presented also includes the business combination accounting effects resulting from the acquisition including, historical interest expense, adjustments to interest expense for certain provisions in the asset purchase agreement, adjustments for transaction-related expenses, adjustments for salary and benefits for certain employees, and amortization charges from acquired intangible assets were combined at the beginning of the earliest period presented. The unaudited pro forma supplemental results have been prepared based on estimates and assumptions, which the Company believes are reasonable and are not necessarily indicative of the consolidated financial position or results of operations had the acquisition occurred at the beginning of the earliest period presented, nor of future results of operations. For purposes of the pro forma presentation, the financial results of Interpoint for the three and nine months ended September 30, 2011 have been combined with the results of the Company for the three and nine months ended October 31, 2011. The Meta results for the three and nine months ended October 31, 2011 and 2012 are based on the three and nine months ended

September 30, 2011 and 2012. Subsequent to the acquisition, the Meta results will be recorded based on the Company’s fiscal year-end. The unaudited pro forma results are as follows (in thousands):

   Three Months Ended
October 31,
 
   2012   2011 

Revenue

  $7,129    $6,817  

Net income (loss)

   1,231     (1,393

Net income (loss) attributable to common shareholders

   1,197     (1,572

Income (loss) per share:

    

Basic

  $0.10    $(0.22

Diluted

  $0.08    $(0.22

                        
   Nine Months Ended
October 31,
 
   2012   2011 

Revenue

   22,733     19,196  

Net income (loss)

   1,249     (6,762

Net income (loss) attributable to common shareholders

   798     (7,302

Income (loss) per share:

    

Basic

  $0.07    $(0.73

Diluted

  $0.06    $(0.73



NOTE D – EQUITY AWARDS AND PRIVATE PLACEMENT INVESTMENT

On August 16, 2012, we completed a $12,000,000 private placement investment (“private placement investment”) with affiliated funds and accounts of Great Point Partners, LLC, and Noro-Moseley Partners VI, L.P., and another investor. The investment consisted of the following instruments: issuance of 2,416,785 shares of a new Series A 0% Redeemable Convertible Preferred Stock (“Series A Preferred Stock”) at $3.00 per share, common stock warrants (“warrants”) exercisable for up to 1,200,000 shares of our common stock at an exercise price of $3.99 per share, and convertible subordinated notes payable in the aggregate principal amount of $5,699,577, which upon shareholder approval, convert into 1,583,220 shares of Series A Preferred Stock. The proceeds were allocated among the instruments as follows.

   Balance at August 16, 2012 

Instruments:

  

Series A Preferred Stock

  $6,546,146  

Convertible subordinated notes payable

   3,765,738  

Warrants

   1,688,116  
  

 

 

 

Total investment

  $12,000,000  
  

 

 

 

We incurred legal, placement and other advisor fees of approximately $1,894,000, including $754,000 in costs for warrants issued to placement agents. The total transaction costs were allocated among the instruments of the private placement investment based on their relative fair values as follows: approximately $611,000 to subordinated convertible notes as deferred financing costs, approximately $1,020,000 to Series A Preferred Stock as discount on Series A Preferred Stock and approximately $263,000 to warrants as a charge to additional paid in capital.

— DERIVATIVE LIABILITIES


Series A Convertible Preferred Stock

In connection with the private placement investment, we issued 2,416,785 shares of Series A Preferred Stock at $3.00 per share. Each share of the Series A Preferred Stock is convertible into one share of our common stock. The price per share of Series A Preferred Stock and the conversion price for the common stock was less than the “market value” of the common stock (as defined in the rules of the Nasdaq Stock Market) on the date of execution of the definitive agreements. The Series A Preferred Stock does not pay a dividend, however the holders are entitled to receive dividends on shares of Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock. The Series A Preferred Stock have voting rights on a modified as-if-converted-to-common-stock-basis. The Series A Preferred Stock has a non-participating liquidation right equal to the original issue price plus accrued unpaid dividends, which are senior to the Company’s common stock. The Series A Preferred Stock can be converted to common shares at any time by the holders, or at the option of the Company if the arithmetic average of the daily volume weighted average price of the common stock for the ten day period prior to the measurement date is greater than $8.00 per share, and the average daily trading volume for the sixty day period immediately prior to the measurement date exceeds 100,000 shares.

The allocation of the proceeds and transaction costs based on relative fair values of the instruments resulted in recognition of a discount on the Series A Preferred Stock of approximately $4,410,000, including discount from beneficial conversion feature of approximately $2,686,000, which will be amortized from the date of issuance to the earliest redemption date. For the three and nine months period ended October 31, 2012, we recognized approximately $139,000 of amortization of the discount on Series A Preferred Stock as deemed dividends charged to additional paid in capital. The value of the beneficial conversion feature is calculated as the difference between the effective conversion price of the Series A Preferred Stock and the fair market value of the common stock into which the Series A Preferred Stock are convertible at the commitment date.

At any time following August 31, 2016, each share of Series A Preferred Stock is redeemable at the option of the holder for an amount equal to the initial issuance price of $3.00 (adjusted to reflect stock splits, stock dividends or like events) plus any accrued and unpaid dividends thereon. The Series A Preferred Stock are classified as temporary equity as the securities are redeemable solely at the option of the holder.

Common Stock Warrants

In conjunction with the private placement investment, wethe Company issued common stock warrants exercisable for up to 1,200,000 shares of our common stock at an exercise price of $3.99$3.99 per share. The warrants can be exercisedwere initially classified in whole orstockholders' equity as additional paid in part duringcapital at the period beginning on February 17, 2013 until 5 years from such initial exercise date. The warrants also include a cashless exercise option which allows the holder to receive a number of shares of common stock based on an agreed upon formula in exchange for the warrant rather than paying cash to exercise.

The proceeds,allocated amount, net of allocated transaction costs, allocated to the warrants of approximately $1,425,000 were classified as equity on August 16, 2012, the date of issuance.$1,425,000. Effective October 31, 2012, upon shareholder approval of antidilutionanti-dilution provisions that reset the warrants’warrants' exercise price if a dilutive issuance occurs, the warrants were reclassified as non-current derivative liabilities. The provisions require the exercise price to reset to the lower price at which the dilutive issuance is consummated, if the dilutive issuance occurs prior to the second anniversary of the warrants’ issuance. If a dilutive issuance occurs after the second anniversary of the warrants’ issuance, then the exercise price will be reset in accordance with a weighted average formula that provides for a partial reset, based on the number of shares raised in the dilutive issuance relative to the number of common stock equivalents outstanding at the time of the dilutive issuance. The change in fair value of the warrants was accounted for as an adjustment to stockholders’ equity for the period between the date of the contract’s last classification as equity to the date of reclassification to liability. The fair value of the warrants was approximately $4,139,000$4,139,000 at October 31, 2012.

On October 19, 2012, we also issued 200,000with the difference between the fair value and carrying value recorded to additional paid in capital. Effective as of the reclassification as derivative liabilities, the warrants to our placement agentsare re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period as a portioncredit or charge to miscellaneous income (expense). The fair value of the feeswarrants at April 30, 2013 was approximately $4,956,000, with the increase in fair value since January 31, 2013 of approximately $645,000 recognized as miscellaneous expense in the consolidated statements of operations. The estimated fair value of the warrant liabilities as of April 30, 2013 was computed using Monte-Carlo simulations based on the following assumptions: annual volatility of 70%; risk-free rate of 0.7%, dividend yield of 0.0% and expected life of approximately five years. The model also included assumptions to account for services renderedanti-dilutive provisions within the warrant agreement.


During the three months ended April 30, 2013, the Company recorded an immaterial correction of an error regarding the valuation of its common stock warrants originated during the third quarter of fiscal 2012 in theconjunction with its private placement investment. The warrants have an initial exercise dateCompany concluded there was a cumulative $19,000 overstatement of May 1, 2013 and are exercisable for a five year term thereafter at a stated exercise pricethe loss before income taxes on its condensed consolidated statement of $4.06 per share and could be exercised in whole or in part at any time. The warrants also included a cashless exercise option which allowed the holder to receive a number of shares of common stock based on an agreed upon formula in exchangeoperations for the warrants rather than paying cash to exercise.fiscal year-ended January 31, 2013, as previously reported. The warrants have no reset provisions. The warrants had a grant date fair valueaforementioned cumulative $19,000 overstatement has been recorded in the condensed consolidated statement of $754,000, and are classified as equity onoperations for the balance sheet.

Convertible Subordinated Notes

Please see Note G - Debt

Equity Awards

During the ninethree months ended OctoberApril 30, 2013. The January 31, 2012, we granted 762,500 options with2013 condensed consolidated balance sheet, as previously reported, reflects a weighted average exercise price$51,000 overstatement of $3.08 per share. During the same period, 258,271 options expired with an average exercise pricedeferred financing costs, a cumulative $150,000 understatement of $1.87 per share and 43,999 options were exercised under all plans.

During the nine months ended October 31, 2011, we granted 1,104,000 options with a weighted average exercise price of $1.90 per share. During the same period 127,916 options expired with an average exercise price of $1.88 per share and 32,598 options were exercised under all plans.

The fair value of each option grant during the nine months ended October 31, 2012 and October 31, 2011 was estimated at the date of the grants using a Black-Scholes option pricing model with the following weighted average assumptions:

At the October 31, 2012 special meeting of shareholders, 500,000 additional shares were approved for the 2005 Incentive Compensation Plan.

   For the nine
months ended,
October 31, 2012
  For the nine
months ended,
October 31, 2011
 

Risk-free interest rate

   0.33  1.26

Dividend yield

   —      —    

Current weighted-average volatility factor of the expected market price of Common Stock

   0.58    0.53  

Weighted-average expected life of stock options

   5 years    5 years  

Forfeiture rate

   0  0

During the nine months ended October 31, 2012, we granted 137,325 restricted shares of common stock with a weighted average fair value of $2.01. These shares are subject to the 2005 Incentive Compensation Plan as amended, and are granted to certain independent members of the Board of Directors and employees. The shares have an approximate one-year restriction period.

During the nine months ended October 31, 2011, we granted 110,412 restricted stock shares with a weighted average fair value of $1.68 per share, and 223,090 restricted stock shares with a weighted average fair value of $1.92 had their restriction period lapse. These shares were subject to the 2005 Incentive Compensation Plan as amended, and are granted to certain independent members of the Board of Directors and employees. The shares had an approximate one-year restriction period.

During the nine months ended October 31, 2011, the Company granted 25,000 restricted stock shares as executive inducement grants with a weighted average fair value of $1.91 per share. The restrictions lapsed immediately upon the grant of the shares, and the Company recognized $48,000 of compensation expense for the nine months ended October 31, 2011 relating to these inducement grants. These executive inducement grants were approved by the board pursuant to Nasdaq Marketplace Rule 5635(c)(4). The terms of the grants are nearly as practicable identical to the terms and conditions of the Company’s 2005 Incentive Compensation Plan.

NOTE E – EARNINGS PER SHARE

Diluted net earnings (loss) per share of common stock reflects the potential dilution that could occur from restricted shares and if stock options, stock purchase plan commitments, and warrants were exercised (under the treasury stock method) and thedeemed dividends on Series A Preferred Stock, a $7,000 overstatement of the Series A preferred stock, and a $602,000 overstatement of additional paid in capital. These aforementioned condensed consolidated balance sheet adjustments have been recorded on the April 30,


11

Index to Financial Statements
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

2013 condensed consolidated balance sheet as presented herein. The Company concluded that the impact of the corrections were converted (on an as-if-converted basis) into shares of our common stock,not quantitatively and qualitatively material to the prior fiscal year, and the respective quarters ended in 2012 and 2013.

NOTE E — LEASES
The Company rents office and data center space and equipment under certain circumstances,non-cancelable operating leases that then would share in our earnings. A reconciliation of basicexpire at various times through fiscal year 2018. Future minimum lease payments under non-cancelable operating leases for the next five fiscal years and diluted weighted average shares for basic and diluted EPS, as well as anti-dilutive securities isthereafter are as follows:

   Three Months Ended, 
   October 31, 2012  October 31, 2011 

Numerator for Basic and Diluted Earnings per Share:

   

Net earnings

  $2,399,637   $295,766  

Less: deemed dividends on Series A Preferred Stock

   (139,133  —    
  

 

 

  

 

 

 

Net earnings attributable to common Shareholders

   2,260,504    295,766  
  

 

 

  

 

 

 

Denominator for basic earnings per share weighted average shares

   12,393,352    9,943,567  

Effect of dilutive securities

   

Stock options

   674,352    15,380  

Restricted shares

   36,962    —    

Series A Preferred Stock

   1,996,475    —    

Warrants

   264,097    —    
  

 

 

  

 

 

 

Denominator for basic earnings per share, with assumed conversions

   15,365,238    9,958,947  
  

 

 

  

 

 

 

Basic net earnings per common share

  $0.18   $0.03  
  

 

 

  

 

 

 

Diluted net earnings per common share

  $0.15   $0.03  
  

 

 

  

 

 

 

Anti-dilutive securities:

   

Stock options, out-of-the-money

   71,500    1,739,551  
  

 

 

  

 

 

 

Warrants, out-of-the-money

   —      —    
  

 

 

  

 

 

 
   Nine Months Ended, 
   October 31, 2012  October 31, 2011 

Numerator for Basic and Diluted Earnings per Share:

   

Net earnings

  $2,427,995   $8,051  

Less: deemed dividends on Series A Preferred Stock

   (139,133  —    
  

 

 

  

 

 

 

Net earnings attributable to common Shareholders

   2,288,862    8,051  
  

 

 

  

 

 

 

Denominator for basic earnings per share weighted average shares

   11,346,428    9,823,937  

Effect of dilutive securities

   

Stock options

   357,554    13,813  

Restricted stock

   42,925    —    

Series A Preferred Stock

   670,349    —    

Warrants

   —      —    
  

 

 

  

 

 

 

Denominator for basic earnings per share, with assumed conversions

   12,417,256    9,837,750  
  

 

 

  

 

 

 

Basic net earnings per common share

  $0.20   $0.00  
  

 

 

  

 

 

 

Diluted net earnings per common share

  $0.18   $0.00  
  

 

 

  

 

 

 

Anti-dilutive securities:

   

Stock options, out-of-the-money

   486,000    1,432,967  
  

 

 

  

 

 

 

Warrants, out-of-the-money

   1,400,000    —    
  

 

 

  

 

 

 


 Facilities Equipment Fiscal Year Totals
2013 (nine months remaining)$666,000
 $135,000
 $801,000
2014750,000
 162,000
 912,000
2015322,000
 40,000
 362,000
2016162,000
 2,000
 164,000
2017167,000
 1,000
 168,000
Thereafter85,000
 
 85,000
Total$2,152,000
 $340,000
 $2,492,000

Rent and leasing expense for facilities and equipment was approximately $236,000 and $196,000 for the three months ended April 30, 2013 and 2012, respectively.

NOTE F – CONTRACTUAL OBLIGATIONS

The following table details the remaining obligations, by fiscal year, as of the end of the quarter (in thousands):

       2012           2013           2014           2015           2016       Thereafter   Totals 

Operating leases

  $310     874     723     322     162     251     2,642  

Senior term loan

   313     1,250     3,437     —       —       —       5,000  

Subordinated term loan

   —       —       9,000     —       —       —       9,000  

Convertible subordinated notes payable (1)

   —       —       —       —       —       —       —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  $623     2,124     13,160     322     162     251     16,642  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

(1)The convertible subordinated notes payable were converted on November 1, 2012. See Note I for further details.

On April 10, 2012, we entered into an amended lease obligation to lease 8,582 square feet of office space in our current building at 1230 Peachtree NE in Atlanta, GA. The lease commences upon taking possession of the space and ends 72 months thereafter. We took possession of the space on August 1, 2012. Upon relocation, we completely vacated the previously leased premises within the building. The provisions of the lease provide for rent abatement for the first four months of the lease term, and a moving allowance of approximately $17,000. Upon taking possession of the premises, the rent abatement and allowance has been aggregated with the total expected rental expense, and amortized on a straight line basis over the term of the lease.

As part of the Meta acquisition, we assumed a lease obligation for office space at 330 Seventh Avenue in New York, NY. The balance of the lease term runs through August of 2014.

NOTE G – DEBT

Term Loan and Line of Credit
On December 7, 2011, in conjunction with the Interpoint acquisition, the Company entered into a subordinated credit agreement with Fifth Third Bank in which the bank provided the Company with a

   Loan Balance at
October  31, 2012
   Accrued interest
at  October 31,
2012
 

Senior term loan

   5,000,000     60,000  

Subordinated term loan (1)

   9,000,000     211,000  

Line of credit

   —       2,000  

(1)Accrued interest includes accruals for success fees of $160,000.

$4,120,000 term loan, which was scheduled to mature on December 7, 2013, and a revolving line of credit, which was scheduled to mature on October 1, 2013.


In conjunction with the Meta acquisition, on August 16, 2012, wethe Company amended our currentthe subordinated term loan and line of credit agreements with Fifth Third Bank, whereby Fifth Third Bank provided usthe Company with a $5,000,000$5,000,000 revolving line of credit, a $5,000,000$5,000,000 senior term loan and a $9,000,000$9,000,000 subordinated term loan, a portion of which was used to refinance the previously outstanding $4,120,000$4,120,000 subordinated term loan. These new term loans and revolving line of credit mature on August 16, 2014. Additionally, as part of the refinancing in August 2012, wethe Company mutually agreed to settle the success fee included in the previous subordinated term loan for $700,000. We$700,000. The difference between the $233,000 success fee accrued through the date of the amendment and the amount paid was recorded to deferred financing costs and is being amortized over the term of the amended loan. The Company paid a commitment fee in connection with the senior term loan of $75,000,$75,000, which is included in deferred financing costs. We

The Company will be required to pay a success fee in accordance with the amended subordinated term loan, which is recorded in interest expense.expense as accrued over the term of the loan. The success fee is due on the date the entire principal balance of the loan becomes due. The success fee is accrued in accordance with the terms of the loan in an amount necessary to provide the lender a 17% internal rate of return through the date the success fee becomes due.

These new term loans and revolving line of credit mature on August 16, 2014. The loans are secured by substantially all of ourthe Company's assets. The senior term loan principal balance is payable in monthly installments of approximately $104,000 which commenced in November 2012, and and will continue through the maturity date, with the full remaining unpaid principal balance due at maturity. The entire unpaid principal balance of the subordinated term loan is due at maturity. Borrowings under the senior term loan bear interest at a rate of LIBOR (0.21%(0.20% at October 31, 2012)April 30, 2013) plus 5.50%, and borrowings under the subordinated term loan bear interest at 10% from August 16, 2012 and thereafter. Accrued and unpaid interest on the senior and subordinated term loans is due monthly through maturity. Borrowings under the revolving loan bear interest at a rate equal to LIBOR plus 3.00%. A commitment fee of 0.40% will be incurred on the unused revolving line of credit balance, and is payable quarterly. There are currently At April 30, 2013, the Company had no draws on outstanding borrowings under the line of credit, with $2,000and had accrued approximately $5,000 in accruedunused balance commitment fees. The proceeds of these loans were used to finance the cash portion of the acquisition purchase price and to cover any additional operating costs as a result of the Meta acquisition.


The Company evaluated the subordinated term loan and revolving line of credit for modification accounting. The Company evaluated the debt restructuring to determine if it was either a modification or extinguishment. The Company concluded that the

12

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

restructuring qualifed as a modification. As such, fees paid to or received from the creditor were capitalized and are being amortized to interest expense over the remaining term of the restructured debt using the effective interest method.
The significant covenants as set forth in the term loans and line of credit are as follows: (i) maintain adjusted EBITDA as of the end of any fiscal quarter greater than $5,000,000,$5,000,000, (after consideration of certain acquisition and transaction costs) on a trailing four fiscal quarter basis beginning October 31, 2012; (ii) maintain a fixed charge coverage ratio for the fiscal quarter ending January 31, 20122013 and each April 30, July 31, October 31, and January 31 of not less than 1.50:1.50:1 calculated quarterly for the period from October 31, 20112012 to the date of measurement for the quarters ending January 31, 2012,2013, April 30, 20122013 and July 31, 20122013 and on a trailing four quarter basis thereafter; (iii) on a consolidated basis, maintain ratio of funded debt to adjusted EBITDA as of the end of any fiscal quarter less than 3:3:1, calculated quarterly on a trailing four fiscal quarter basis beginning October 31, 2012. We wereThe Company was in compliance with all loan covenants at October 31, 2012.

Convertible NotesApril 30, 2013

On December 7, 2011, as parta result of obtaining a waiver from its lender.

Outstanding principal balances on long-term debt consisted of the purchasefollowing at:
  Balance at April 30, 2013 Balance at January 31, 2013
Senior term loan $4,375,000
 $4,688,000
Subordinated term loan 9,000,000
 9,000,000
Line of credit 
 
Total 13,375,000
 13,688,000
Less: Current portion 1,250,000
 1,250,000
Non-current portion of long-term debt $12,125,000
 $12,438,000

Future principal repayments of long-term debt consisted of the assets of Interpoint, we issued a convertible promissory note (the “Convertible Note”) for $3,000,000. The note accrued interestfollowing at a per annum rate of 8% from the date of the note until the earlier of conversion or payment in full of all outstanding principal and accrued interest. Interest is payable quarterly in arrears on the first day of March, June, September, and December.

On June 15, 2012, Interpoint elected to convert the balance of principal and interest on the note outstanding, net of working capital adjustments and related accrued interest owed to us, for 1,529,729 shares of common stock at $2.00 per share. Net loss from conversion was approximately $57,000 for the three and nine months ended October 31, 2012.

In conjunction with the private placement, we issued convertible subordinated notes in the aggregate principal amount of $5,699,577, which upon shareholder approval, convert into 1,583,220 shares of Series A Preferred Stock. The allocation of the proceeds to the subordinated convertible notes resulted in a debt discount of approximately $1,934,000, which will be amortized over the period from issue date to maturity date. For the three and nine months ended October 31, 2012, we recorded approximately $112,000 of debt discount amortization. In addition, the notes accrue interest at a per annum rate of 12% from issue date until the earlier of conversion or payment in full of all outstanding principal and accrued interest. Half of the interest accrued is payable monthly, with the remaining in arrears and payable upon conversion of the note. The carrying amount of the convertible subordinated notes payable was approximately $3,877,000, net of approximately $1,822,000 unamortized discount, at October 31, 2012. On November 1, 2012, upon shareholder approval, the convertible subordinated notes were converted into shares of Series A Preferred Stock (see Note I).

April 30, 2013:

  Payments Due by Period
  2013 2014
Senior term loan $937,000
 $3,438,000
Subordinated term loan 
 9,000,000
Line of credit 
 
Total principal repayments $937,000
 $12,438,000
Contingent Earn-Out Provision

As part of the asset purchase, Interpoint is entitled to receive additional consideration contingent upon certain financial performance measurements during a one year earn-out period commencing June 30, 2012 and ending on June 30, 2013. The earn-out consideration is calculated as twice the recurring revenue for the earn-out period recognized by the acquired Interpoint operations from specific contracts defined in the asset purchase agreement, plus one times Interpoint revenue derived from ourthe Company's customers, less $3,500,000.$3,500,000. The earn-out consideration, if any, will be paid no later than July 31, 2013 in cash or through the issuance of a note with terms identical to the terms of the Convertible Note (which was converted on June 15, 2012, please see "Note F - Debt" in the Notes to the Consolidated Financial Statements as part of the annual report on Form 10-K for the year ended January 31, 2013), except with respect to issue date, conversion date and prepayment date. The earn-out note restricts conversion or prepayment at any time prior to the one year anniversary of the issue date.

Interpoint is entitled to additional earn-out consideration

As of fifty percent of any license sales ofApril 30, 2013, the developed software acquired, to specific clients as defined in the asset purchase agreement, for any sales prior to December 31, 2012.

At October 31, 2012, we estimateCompany estimates the payment obligation in connection with the earn-out will be $1,320,000, an increase$1,320,000. As of approximately $87,000, whichJanuary 31, 2013, the Company estimated the payment obligation to be $1,320,000. No change in value of the estimated earn-out was recorded as additionalfor the three months ended April 30, 2013.



NOTE G — INCOME TAXES

13

Index to Financial Statements
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Income tax expense inconsists of federal, state and local tax provisions. For the third quarterthree months ended April 30, 2013 and 2012, the Company recorded federal tax provisions of fiscal 2012.

$11,000 and zero, respectively. For the three months ended April 30, 2013 and 2012 the Company recorded state and local tax provisions of $9,000 and $9,000, respectively.




NOTE H – COMMITMENTS AND CONTINGENCIES— STOCK BASED COMPENSATION
Stock Option Plans
The summary of stock option activity for the

We have entered into employment agreements with our officersthree months ended April 30, 2013:



Three Months Ended

April 30, 2013

Options Weighted Average Exercise Price
Outstanding — beginning of period2,685,237
 

Granted171,000
 6.81
Exercised(36,994) 1.66
Forfeit/Expired(65,500) 1.96
Outstanding — end of period2,753,743
 $3.41
Exercisable — end of period850,788
 $2.41
Weighted average grant date fair value of options granted during year$3.07
  

As of April 30, 2013, there was approximately $2,951,000 of unrecognized compensation expense related to unvested options that will be recognized over a remaining weighted average period of three years. The 2013 and certain employees that generally provide annual salary, a minimum bonus, discretionary bonus, and stock incentive provisions.

NOTE I – SUBSEQUENT EVENTS2012

We evaluated all events or transactions that occurred after October 31, 2012 through stock-based compensation was estimated at the date we issued these financial statements.

On November 1, 2012,of grant using a Black-Scholes option pricing model with the convertible subordinated notes previously issued by us on August 16, 2012 were converted into sharesfollowing weighted average assumptions.


 Three Months Ended
 April 30, 2013 April 30, 2012
Expected life5 years
 5 years
Risk-free interest rate0.39% 0.51%
Weighted average volatility factor0.54
 0.53
Dividend yield
 
That cost is expected to be recognized over a remaining weighted average period of our Series A 0% Convertible Preferred Stock.three years. The convertible subordinated notes had an aggregate principal amountexpense associated with stock option awards was approximately $402,000 and $128,000, for the three months ended April 30, 2013 and 2012, respectively. Cash received from exercise of $5,699,577options and converted into an aggregate of 1,583,210 shares of Preferred Stock. the employee stock purchase plan was approximately $62,000 and zero, respectively, for the three months ended April 30, 2013 and 2012.

14

Index to Financial Statements
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Restricted Stock
The issuanceCompany grants restricted stock awards under the 2005 Incentive Compensation Plan to associates and members of the convertible subordinated notesboard of directors. The Company has also issued restricted shares as inducement grants to executives. The restrictions on the shares granted generally lapse over a one year term of continuous employment from the date of grant. The grant date fair value per share of restricted stock, which is the stock price on the grant date, is expensed on a straight-line basis as the restriction period lapses. The shares represented by restricted stock awards are considered outstanding at the grant date, as the recipients are entitled to voting rights. A summary of restricted stock award activity for the period is presented below:


Non-vested Number of Shares Weighted Average Grant Date Fair Value
Non-vested balance at January 31, 2013137,325
 $2.01
Granted
 
Vested
 
Forfeited/expired
 
Non-vested balance at April 30, 2013137,325
 $2.01

At April 30, 2013, there was previously disclosed inapproximately $17,000 of compensation cost that has not yet been recognized related to restricted stock awards. That cost is expected to be recognized over a remaining period of one year or less.
The expense associated with restricted stock awards was approximately $65,000 and $50,000 for the Current Report on Form 8-K filed on August 21, 2012. We incurred a loss upon conversion of $5,898,000 on November 1, 2012.

three months ended April 30, 2013 and 2012, respectively.



15

Index to Financial Statements

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

FORWARD-LOOKING STATEMENTS
In addition to historical information contained herein, this quarterly report on Form 10-Q contains forward-looking statements relating to plans, strategies, expectations, intentions, etc. of Streamline Health Solutions, Inc. (“we”, “us”, “our”, or “our”the "Company") and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained herein are no guarantee of future performance and are subject to certain risks and uncertainties that are difficult to predict and actual results could differ materially from those reflected in the forward-looking statements. These risks and uncertainties include, but are not limited to, the impact of competitive products and pricing, product demand and market acceptance, new product development, key strategic alliances with vendors that resell our products, our ability to control costs, availability of products produced from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information system budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accountings Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which we operate and nationally, and our ability to maintain compliance with the terms of our credit facilities, and other risk factors that might cause such differences including those discussed herein, including, but not limited to, discussions in the sections entitled Part I, “Item 11. Financial Statements” and “Item 22. Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In addition, other written or oral statements that constitute forward-looking statements may be made by us or on our behalf. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’smanagement's analysis only as of the date thereof. We undertake no obligation to publicly revise these forward-looking statements, to reflect events or circumstances that arise after the date hereof. Readers should carefully review the risk factors described in this and other documents we file from time to time with the Securities and Exchange Commission, including the annual report on Form 10-K, quarterly reports on Form 10-Q and any current reports on Form 8-K.

Our


The following discussion and analysis should be read in conjunction with the Company's Condensed Consolidated Financial Statements and related Notes included elsewhere in this Quarterly Report on From 10-Q.


16

Index to Financial Statements

Results of Operations
Acquisition of Meta Health Technology, Inc.
On August 16, 2012, the Company acquired substantially all of the outstanding stock of Meta Health Technology, Inc., a New York corporation (“Meta”). The Company paid a total purchase price of approximately $14,790,000, consisting of cash payment of $13,288,000 and the issuance of 393,086 shares of our financial condition and resultscommon stock at an agreed upon price of operations are based upon our consolidated financial statements,$4.07 per share. The fair value of the common stock at the date of issuance was $3.82. As of October 31, 2012, the Company had acquired 100% of Meta’s outstanding shares. The purchase price is subject to certain adjustments related principally to the delivered working capital level, which have been prepared in accordance with accounting principles generally acceptedwill be settled in the United States.third quarter of fiscal 2013, and/or indemnification provisions. Under the acquisition method of accounting, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The preparationoperations of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent liabilities. On an ongoing basis, we evaluate our estimates, including those related to product revenues, bad debts, capitalized software development costs, income taxes, support contracts, contingencies, and litigation. We base our estimates on historical experience and on various other assumptions that we believeMeta are reasonable under the circumstances,consolidated with the results of which form the basis for making judgments about the carrying valuesCompany from August 16, 2012.
Statement of assets and liabilities, and revenue and expense recognition. Actual results may differ from these estimates under different assumptions or conditions.

Operating Results

We recognized revenues in the three and nine month periods ending October 31, 2012 of $6,534,000 and $17,029,000, compared to $4,312,000 and $12,598,000Operations for the comparable prior year periods; an increase of $2,222,000 and $4,431,000 or 52% and 35%, respectively. Revenues are derived primarily from recurring revenues recognized from softwarequarters ended (amounts in thousands):



Three Months Ended 
 

April 30, 2013 April 30, 2012 Change % Change
Systems sales$324
 $354
 $(30) (8)%
Professional services919
 1,122
 (203) (18)%
Maintenance and support3,381
 2,352
 1,029
 44 %
Software as a service1,849
 1,618
 231
 14 %
Total revenues6,473
 5,446
 1,027
 19 %
Cost of sales3,177
 2,647
 530
 20 %
Selling, general and administrative3,581
 1,670
 1,911
 114 %
Product research and development1,097
 456
 641
 141 %
Total operating expenses7,855
 4,773
 3,082
 65 %
Operating profit (loss)(1,382) 673
 (2,055) (305)%
Other income (expense), net(1,309) (172) (1,137) 661 %
Income tax expense(20) (9) (11) 122 %
Net earnings (loss)$(2,710) $492
 $(3,202) (651)%
Adjusted EBITDA(1)$685
 $1,713
 $(1,028) (60)%
_______________
(1)Non-GAAP measure meaning earnings before interest, tax, depreciation, amortization, stock-based compensation expense, transactional and one-time costs. See “Use of Non-GAAP Financial Measures” below for additional information and reconciliation.

17

Index to Financial Statements

The following table sets forth, for each fiscal quarter indicated, certain operating data as a service (referred to herein as “SaaS”) and maintenance contracts. We incurred a quarterly operating loss of $302,000, and a year-to-date operating profit of $346,000, for the periods ended October 31, 2012. In the prior year comparable periods we earned operating profits of $364,000 and $130,000, respectively. Operating expenses for the three and nine month periods ending October 31, 2012 were $6,836,000 and $16,682,000, compared to $3,949,000 and $12,468,000 in the comparable prior year periods; an increase of $2,887,000 and $4,214,000, or 73% and 34%, respectively, over the prior year comparable periods.

Our revenues from proprietary systems sales have varied, and may continue to vary, significantly from quarter-to-quarter because of the volume and timing of systems sales and delivery. Professional services revenues also fluctuate from quarter-to-quarter because of the timing of the implementation services, project management, and timing of the recognition of revenues under generally accepted accounting principles. Conversely, revenues from SaaS, and maintenance services do not fluctuate significantly from quarter-to-quarter, but have been increasing, on an annual basis, as the number of customers increase or customers expand their solutions. Substantial portions of the operating expenses are fixed; therefore operating profits are expected to vary depending primarily on the mix of proprietary system revenue versus SaaS revenue.

percentages:

Statement of Operations(1)

   Three Months Ended October 31,  Nine Months Ended October 31, 
   2012  2011  2012  2011 

Systems sales

   4  5  4  4

Professional services

   17    19    19    21  

Maintenance and support

   48    52    46    52  

Software as a service

   31    22    31    22  
  

 

 

  

 

 

  

 

 

  

 

 

 

Total revenues

   100    100    100    100  
  

 

 

  

 

 

  

 

 

  

 

 

 

Cost of sales

   47    50    47    53  

Selling, general and administrative

   45    35    40    38  

Product research and development

   13    7    11    8  
  

 

 

  

 

 

  

 

 

  

 

 

 

Total operating expenses

   105    92    98    99  
  

 

 

  

 

 

  

 

 

  

 

 

 

Operating profit (loss)

   (5  8    2    1  

Other income (expense), net

   (13  (1  (8  (1

Income tax benefit

   54    —      21    —    
  

 

 

  

 

 

  

 

 

  

 

 

 

Net earnings

   37  7  14  (0)% 
  

 

 

  

 

 

  

 

 

  

 

 

 

Cost of systems sales

   247  251  269  332
  

 

 

  

 

 

  

 

 

  

 

 

 

Cost of professional services

   78  63  61  71
  

 

 

  

 

 

  

 

 

  

 

 

 

Cost of maintenance and support

   29  22  30  25
  

 

 

  

 

 

  

 

 

  

 

 

 

Cost of software as a service

   27  50  35  48
  

 

 

  

 

 

  

 

 

  

 

 

 

Operations(1)


Three Months Ended

April 30, 2013 April 30, 2012
Systems sales5.0 % 6.5 %
Professional services14.2
 20.6
Maintenance and support52.2
 43.2
Software as a service28.6
 29.7
Total revenues100.0 % 100.0 %
Cost of sales49.1
 48.6
Selling, general and administrative55.3
 30.7
Product research and development16.9
 8.4
Total operating expenses121.4
 87.6
Operating profit (loss)(21.4) 12.4
Other income (expense), net(20.2) (3.2)
Income tax net loss(0.3) (0.2)
Net earnings (loss)(41.9)% 9.0 %
Cost of systems sales197.1 % 193.9 %
Cost of services, maintenance and support22.7 % 15.9 %
Cost of software as a service31.3 % 42.2 %
_______________
(1)Because a significant percentage of the operating costs are incurred at levels that are not necessarily correlated with revenue levels, a variation in the timing of systems sales and installations and the resulting revenue recognition can cause significant variations in operating results. As a result, period-to-period comparisons may not be meaningful with respect to the past operations nor are they necessarily indicative of ourthe future operations of the Company in the near or long-term. The data in the table is presented solely for the purpose of reflecting the relationship of various operating elements to revenues for the periods indicated.

Revenues

Revenues consisted of the following (in thousands):

   Three Months Ended,        
   October 31, 2012   October 31, 2011   Change  % Change 

Proprietary software(1)

  $27    $24    $3    12

Term licenses

   144     —       144    —  

Hardware & third party software(1)

   119     209     (90  (43)% 

Professional services(2)

   1,090     833     257    31

Maintenance & support(3)

   3,148     2,280     868    38

Software as a service(4)

   2,006     966     1,040    107
  

 

 

   

 

 

   

 

 

  

 

 

 

Net revenues

  $6,534    $4,312    $2,222    51
  

 

 

   

 

 

   

 

 

  

 

 

 

   Nine Months Ended,        
   October 31, 2012   October 31, 2011   Change  % Change 

Proprietary software(1)

  $162    $76    $86    113

Term licenses

   144     —       144    —  

Hardware & third party software(1)

   414     450     (36  (8)% 

Professional services(2)

   3,154     2,709     445    16

Maintenance & support(3)

   7,797     6,559     1,238    19

Software as a service(4)

   5,358     2,804     2,554    91
  

 

 

   

 

 

   

 

 

  

 

 

 

Net revenues

  $17,029    $12,598    $4,431    35
  

 

 

   

 

 

   

 

 

  

 

 

 



Three Months Ended 
 

April 30, 2013 April 30, 2012 Change % Change
System Sales (1):       
Proprietary software$78
 $120
 $(42) (35)%
Term licenses226
 
 226
  %
Hardware & third party software20
 233
 (213) (91)%
Professional services919
 1,122
 (203) (18)%
Maintenance & support3,381
 2,352
 1,029
 44 %
Software as a service1,849
 1,618
 231
 14 %
Total Revenues$6,473
 $5,445
 $1,028
 19 %
_______________
(1)Proprietary software, hardware, and term licenses are the components of the system sales line item. Term licenses are comprised of Meta software only.
(2)Includes $74,000 and $138,000 of revenue earned from the acquired Interpoint operations for the three and nine month periods ended October 31, 2012, respectively. Includes $191,000 of revenue earned from the acquired Meta operations for the period from August 17, 2012 to October 31, 2012.
(3)Includes maintenance revenue for Meta perpetual licenses and third party software maintenance of $924,000 for the period from August 17, 2012 to October 31, 2012.
(4)Includes $821,000 and $1,941,000 of revenue earned from the acquired Interpoint operations for the three and nine month periods ended October 31, 2012, respectively.

Revenues






18

Index to Financial Statements

Proprietary software and term liceneses — Proprietary software revenues recognized for the three and nine month periodsmonths ended October 31, 2012 were $6,534,000 and $17,029,000 respectively;April 30, 2013 decreased by $42,000, or 35%, over the the prior comparable period. This decrease is attributable to reduced volume of HIM licenses delivered to clients in the current year quarter as compared to $4,312,000 and $12,598,000 respectivelythe prior comparable quarter, which is offset by the delivery of one computer assisted coding ("CAC") license in the comparable periodscurrent quarter. Recurring CAC term license sales of fiscal 2011. The quarterly and year to date increase was primarily attributable to$226,000 are incremental revenues provided by the acquired Meta operations.
Hardware and third party software — Revenues from hardware and third party software sales for the three months ended April 30, 2013 were $19,982, a decrease of $213,000, or 91%, over the the prior comparable period. The decrease in hardware and third party software revenue is primarily attributable to a reduction in customer demand for third party peripheral devices as compared to the prior year comparable period.
Professional services — Revenues from professional services for the three months ended April 30, 2013 were $919,000, a decrease of $203,000, or 18%, from the prior comparable period. Professional services provided by the acquired Meta operations for the three months ended April 30, 2013 were $378,000, and were offset by a decrease of $617,000 in legacy services due to the timing of which revenue could be recognized based on services performed.
Maintenance and support — Revenues from maintenance and support for the three months ended April 30, 2013 were $3,381,000, an increase of $1,029,025, or 44%, from the prior comparable period. The increase in maintenance and support results from revenue provided by the acquired Meta operations of $1,247,000, and was partially offset by planned attrition of certain perpetual license customers. Typically, maintenance renewals include a price increase based on the prevailing consumer price index, or increase in the product set purchased by the client.
Software as a service (SaaS) — Revenues from SaaS for the three months ended April 30, 2013 were $1,849,000, an increase of $231,000, or 14%, from the prior comparable period. This increase is attributable to the recognition of add-on SaaS contracts signed, primarily in our PFS-SaaS product line.

Cost of Sales

  
Three Months Ended    
(in thousands):April 30, 2013 April 30, 2012 Change % Change
Cost of systems sales$639
 $687
 $(48) (7)%
Cost of professional services974
 553
 421
 76 %
Cost of maintenance and support985
 725
 260
 36 %
Cost of software as a service579
 682
 (103) (15)%
Total cost of sales$3,177
 $2,647
 $530
 20 %
The increase in cost of sales for the three months ended April 30, 2013 is primarily the result of incremental operational costs incurred for the acquired Meta operations as well as the amortization of the internally-developed software acquired as part of the Meta acquisition.
Cost of systems sales includes amortization and impairment of capitalized software expenditures, royalties, and the cost of third-party hardware and software. Cost of systems sales, as a percentage of systems sales, varies from period-to-period depending on hardware and software configurations of the systems sold. The relatively fixed cost of the capitalized software amortization, without the addition of any impairment charges, compared to the variable nature of system sales causes these percentages to vary dramatically.
The cost of professional services includes compensation and benefits for personnel, and related expenses. The increase in expense is primarily due to incremental operational costs associated with the acquired Meta operations, as well as increases in staffing for our PFS-SaaS services line.
The cost of maintenance and support includes compensation and benefits for client support personnel and the cost of third party maintenance contracts. The increase in expense is primarily due to incremental operational costs associated with the acquired Meta operations.
The cost of software as a service is relatively fixed, but subject to inflation for the goods and services it requires. The decrease is related to incremental data center costs that were incurred in the prior comparable period that had no comparable expense for the three months ended April 30, 2013.


19

Index to Financial Statements

Selling, General and Administrative Expense

  
Three Months Ended    
(in thousands):April 30, 2013 April 30, 2012 Change % Change
General and administrative expenses$2,843
 $1,195
 $1,648
 138%
Sales and marketing expenses738
 475
 263
 55%
Total selling, general, and administrative$3,581
 $1,670
 $1,911
 114%

General and administrative expenses consist primarily of compensation and related benefits and reimbursable travel and living expenses related to the Company’s executive and administrative staff, general corporate expenses, amortization of intangible assets, and occupancy costs. The increase over the prior year is primarily due to the incremental increase for general and administrative expenses associated with the acquired Meta operations. Amortization of intangible assets added incremental expense to the three months ended April 30, 2013 due to the amortization of assets acquired as part of the acquisition of Interpoint and Meta operations. Acquired Interpoint operations contributed $895,000 and $2,079,000Meta. We recognized approximately $314,000 in incremental revenueamortization expense for the three months ended April 30, 2013 for acquired intangible assets as compared to $72,000 in the prior comparable period. The Company also incurred increased expense due to investor relations and nine month periods ended October 31, 2012.acquisition search activities, as well as additional costs from executive severances and other costs associated with our corporate office move to Atlanta, Georgia.
Sales and marketing expenses consist primarily of compensation and related benefits and reimbursable travel and living expenses related to the Company’s sales and marketing staff; advertising and marketing expenses, including trade shows and similar type sales and marketing expenses. The increase in sales and marketing expense reflects an increase in costs associated with increased trade show activity and other marketing programs.
Product Research and Development

  
Three Months Ended    
(in thousands):April 30, 2013 April 30, 2012 Change % Change
Research and development expense$1,097
 $456
 $641
 141 %
Plus: Capitalized research and development cost460
 507
 (47) (9)%
Total R&D cost$1,557
 $963
 $594
 62 %

Product research and development expenses consist primarily of compensation and related benefits; the use of independent contractors for specific near-term development projects; and an allocated portion of general overhead costs, including occupancy. Research and development expense increased due to higher support for newly released software versions, which also decreased the number of hours available to be capitalized, which is reflected in the capitalized research and development costs. The acquired Meta operations contributed $1,259,000an incremental $386,000 in research and development expenses. Additionally, the hours available for capitalization decreased for the period August 17, 2012HIM product line, and costs not eligible for capitalization increased compared to October 31, 2012. Additionalthe prior comparable period. Research and development expenses for the three months ended April 30, 2013 and 2012, as a percentage of revenues, were 17% and 8%, respectively.
Other Income (Expense)
Interest expense for the three months ended April 30, 2013 and 2012 was $567,000 and $208,000, respectively. Interest expense consists of interest and commitment fees on the line of credit, interest (including accruals for success fees) on the term loans entered into in conjunction with the Interpoint and Meta acquisitions, interest on the convertible note entered into in conjunction with the Interpoint acquisition, and is inclusive of deferred financing cost amortization. Interest expense increased for the three months ended April 30, 2013 primarily because of the increases in recurring revenues from SaaSthe term loan interest and maintenance contracts are primarily duesuccess fees, and amortization of deferred financing costs related to annual increases, new clientsthe Meta acquisition. The Company also recorded a valuation adjustment to its warrants liability, recorded as miscellaneous expense of $645,000, using assumptions made by management to adjust to the current fair market value of the warrants at April 30, 2013.
Provision for Income Taxes
The Company recorded a tax expense of $20,000 and $9,000 for the three months ended April 30, 2013 and 2012 respectively, which have added incremental revenue, or expansionis comprised of servicesestimated federal alternative minimum tax, state and local tax provisions.

20

Index to current clients.

Financial Statements



Backlog

 April 30, 2013 April 30, 2012
Company proprietary software$3,304,000
 $94,000
Hardware and third-party software77,000
 140,000
Professional services8,040,000
 5,240,000
Maintenance and support23,017,000
 10,973,000
Software as a service18,607,000
 15,000,000
Total$53,045,000
 $31,447,000

Backlog

   October 31, 2012   January 31, 2012   October 31, 2011 

Streamline Health proprietary software (1)

  $3,650,000    $181,000    $67,000  

Hardware and third party software

   84,000     194,000     190,000  

Professional services

   4,348,000     5,945,000     4,946,000  

Maintenance and support (2)

   21,535,000     10,504,000     5,374,000  

Software as a service

   19,117,000     10,542,000     6,237,000  
  

 

 

   

 

 

   

 

 

 

Total

  $48,734,000    $27,366,000    $16,814,000  
  

 

 

   

 

 

   

 

 

 

(1)Includes $3,546,000 from Meta operations
(2)Includes $9,460,000 from Meta operations

At October 31, 2012, weApril 30, 2013, the Company had master agreements and purchase orders from clients and remarketing partners for systems and related services which have not been delivered or installed which, if fully performed, would generate future revenues of approximately $48,734,000$53,045,000 compared with $16,814,000$31,447,000 at October 31, 2011.

OurApril 30, 2012.

The Company’s proprietary software backlog consists of signed agreements to purchase software licenses and term licenses. Typically, this is software that is not yet generally available, or the software is generally available and the client has not taken possession of the software. We added $3,546,000 in incremental backlog from Meta term licenses.

Third party

Third-party hardware and software consists of signed agreements to purchase third partythird-party hardware or third partythird-party software licenses that have not been delivered to the client. These are products that we resellthe Company resells as components of solutions clients purchase.the solution a client purchases. The decrease in backlog is primarily due to clients which have made fewer purchases for future systems implementations.a reduction in the volume of third-party sales as opposed to the prior comparable period. These items are expected to be delivered in the next twelve months as implementations commence.

Professional services backlog consists of signed contracts for services that have yet to be performed, or revenues that are deferred.performed. Typically, backlog is recognized within twelve months of the contract signing for services, unless those services are deemed essential to the functionality of software; whereby they are deferred and recognized over a period greater than one year.signing. The increase in backlog from the prior year comparable quarter is due to incremental backlog provided by SaaS-PFSseveral clients acquired in the Interpoint acquisition, incremental backlog from Meta backlog, and is partially offset by revenue recognized outthat signed contracts during fiscal 2012 for add-on solutions, upgrades, or expansion of backlog.

services at additional locations for which contracted services have not yet been performed.

Maintenance and support backlog consists of maintenance agreements for licenses of ourthe Company’s proprietary software and third party hardware and software with clients and remarketing partners for which either an agreement has been signed or a purchase order has been received, or paymentunder a master agreement has been received. IncludedThe Company includes in maintenance and support backlog are the signed client agreements through their respective renewal dates. Typical maintenance contracts are for a one year term and are renewed annually. Clients typically prepay maintenance and support which is billed 30-60 days prior to the beginning of the maintenance period. We do not expect any significant client attrition over the next 12 months. Maintenance and support backlog at October 31, 2012April 30, 2013 was $21,535,000$23,017,000 as compared to $5,374,000$10,973,000 at October 31, 2011.April 30, 2012. A significant portion of thethis increase in maintenance and support backlog is due to one client which signed an extendedbacklog added by Meta maintenance contract for five years,contracts. Additionally, as well as $9,460,000 in incremental backlog from Meta operations. Other factors which increased backlog are add-on solutions sold in fiscal 2011 and the first three quarterspart of fiscal 2012. Additionally, contract renewals contracts are typically subject to an annual increase in fees based on market rates and inflationary metrics.

At October 31, 2012, we haveApril 30, 2013, the Company had entered into SaaSsoftware as a service agreements, which are expected to generate revenues of $19,117,000$18,607,000 through their respective renewal dates in fiscal years 20122013 through 2018. Typical SaaS terms are one to fiveseven years in length. The increase incommencement of revenue recognition for SaaS backlog from October 31, 2011 is primarilyvaries depending on the impact of assumed backlog from the Interpoint acquisition, as well as new contracts signed late in fiscal 2011 through the third quarter of fiscal 2012.

Cost of Sales

Cost of sales consistedsize and complexity of the following (in thousands):

   Three Months Ended,         
   October 31, 2012   October 31, 2011   Change   % Change 

Cost of system sales

  $718    $583    $135     23

Cost of professional services

   855     572     283     49

Cost of maintenance and support

   918     514     404     79

Cost of software as a service

   551     480     71     15
  

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of sales

  $3,042    $2,149    $893     41
  

 

 

   

 

 

   

 

 

   

 

 

 

   Nine Months Ended,        
   October 31, 2012   October 31, 2011   Change  % Change 

Cost of system sales

  $1,937    $1,752    $185    10

Cost of professional services

   1,911     1,924     (13  (1)% 

Cost of maintenance and support

   2,350     1,652     698    42

Cost of software as a service

   1,850     1,335     515    38
  

 

 

   

 

 

   

 

 

  

 

 

 

Total cost of sales

  $8,048    $6,663    $1,385    21
  

 

 

   

 

 

   

 

 

  

 

 

 

Costsystem, the implementation schedule requested by the client, and ultimately the official go-live on the system. Therefore, it is difficult for the Company to accurately predict the revenue it expects to achieve in any particular period.

All of systems sales includes amortizationthe Company’s master agreements are generally non-cancelable but provide that the client may terminate its agreement upon a material breach by the Company, or may delay certain aspects of capitalized software expenditures, royalties, and the costinstallation. There can be no assurance that a client will not cancel all or any portion of third-party hardware and software. The quarterly increasea master agreement or delay portions of the agreement. A termination or delay in the cost of systems sales is primarily the resultone or more phases of an increase in third-party hardware and software sales. The year-to-date increase of $185,000 inagreement, or the cost of systems sales is primarily attributable to the sunsetting of certain products, the general release and subsequent amortization of products during the third quarter, and partially offset by older assets becoming fully amortized.

The cost of professional services includes compensation and benefits for personnel, and related expenses. The quarterly increase in expense is primarily due to a significant increase in staffing, which took place in the second quarter of fiscal 2012. A portionfailure of the increase is also attributableCompany to the incremental increase of $331,000 and $502,000, respectively, in quarterly and year-to-date expense attributable to the inclusion of Interpoint and Meta implementation services.

The cost of maintenance and support includes compensation and benefits for client support personnel and the cost of third party maintenance contracts. The quarterly and year-to-date increase in expense is primarily due to increased support costs experienced in the quarter for certain products in general release.

The cost of software asprocure additional agreements, could have a service is relatively fixed, but is generally subject to annual increases for the goods and services required. Additionally, amortization of internally developed software purchased in the acquisition of Interpoint and Meta of $218,000 and $394,000 was recorded for the three and nine months ended October 31, 2012 respectively. The quarterly and year-to-date increase, net of amortization expense, is primarily attributable to increased personnel and infrastructure costs relative to data center operations to support revenue growth, as well as the incremental costs for SaaS data center operations.

Selling, General and Administrative Expense

Selling, general and administrative expenses consisted of the following (in thousands):

   Three Months Ended,         
   October 31, 2012   October 31, 2011   Change   % Change 

Selling, general, and administrative

  $2,927    $1,495    $1,432     96
  

 

 

   

 

 

   

 

 

   

 

 

 
   Nine Months Ended,         
   October 31, 2012   October 31, 2011   Change   % Change 

Selling, general, and administrative

  $6,801    $4,742    $2,059     43
  

 

 

   

 

 

   

 

 

   

 

 

 

Selling, general and administrative expenses consist primarily of compensation and related benefits and reimbursable travel and living expenses related to our sales, marketing and administrative personnel; advertising and marketing expenses, including trade shows and similar type sales and marketing expenses; and general corporate expenses, including occupancy costs. The quarterly and year-to-date increase over the comparable prior year periods is due to costs incurred as part of the Meta acquisition and integration, as well as general increases in investor relations expenses, professional fees, travel and living expenses, trade show expense, and amortization of intangible assets acquired in the Meta & Interpoint transactions.

Product Research and Development Expense

Product research and development expenses consisted of the following (in thousands):

   Three Months Ended,        
   October 31, 2012   October 31, 2011   Change  % Change 

Product research and development expense

  $867    $304    $563    185

Capitalized software development cost

   601     579     22    3
  

 

 

   

 

 

   

 

 

  

 

 

 

Total R&D cost

  $1,468    $883    $585    66
  

 

 

   

 

 

   

 

 

  

 

 

 
   Nine Months Ended,        
   October 31, 2012   October 31, 2011   Change  % Change 

Product research and development expense

  $1,834    $1,064    $770    72

Capitalized software development cost

   1,571     1,970     (399  (20)% 
  

 

 

   

 

 

   

 

 

  

 

 

 

Total R&D cost

  $3,405    $3,034    $371    12
  

 

 

   

 

 

   

 

 

  

 

 

 

Product research and development expenses consist primarily of compensation and related benefits; the use of independent contractors for specific near-term development projects; and an allocated portion of general overhead costs, including occupancy. Quarterly and year-to-date research and development expenses increased $563,000 and $770,000, respectively, from the prior year comparable periods. The quarterly and year-to-date increases in research and development expense is a result of increased

development time spent on non-capitalizable products as well as incremental expense of $391,000 attributable to Meta research and development. Quarterly and year-to-date capitalized software development costs (not including purchased internally developed software from Meta And Interpoint) decreased as compared to the prior year primarily due to a decrease in costs eligible for capitalization. The total research and development expenditures on a quarterly and year-to-date basis have increased by $585,000 and $371,000, respectively, when considering both capitalized software development costs and non-capitalizable research and development expense; this is primarily due to increases in post general release software hotfixes and reductions in staffing, as well as the addition of Meta research & development.

Other Income (Expense)

Quarterly and year-to-date interest expense for the period ending October 31, 2012 was $895,000 and $1,494,000, respectively, compared to $26,000 and $68,000 in the prior year comparable periods. Interest expense consists of interest and commitment feesmaterial adverse effect on the lineCompany’s financial condition, and results of credit, interest and success fees on the term loans entered into in conjunction with the Interpoint and Meta acquisitions, interest on the convertible notes entered into in conjunction with the Interpoint and Meta acquisitions, loss on the Interpoint note conversion, and amortization of deferred financing costs and discounts on convertible notes payable related to these transactions. The increase over prior comparable three and nine month periods is primarily due to the term loans and convertible note interest as well as accruals for success fees associated with the term loan. Interest expense also includes the impact of the amortization of deferred financing costs of $79,000 and $118,000, and $112,000 of amortization of debt discounts, for the three and nine month periods ended October 31, 2012, as compared to zero for the prior comparable periods. Other income and expense consists of foreign currency exchange gains and advertising sponsorships.

Income Taxes Benefit (Expense)

The quarterly and year-to-date tax provision in fiscal 2012 and 2011 is comprised of state and local provisions. As a result of the deferred tax liabilities recorded in conjunction with the Meta acquisition, we were able to reduce our valuation allowance by approximately $3,600,000 representing the significant deferred tax benefit recorded in the three and nine months ended October 31, 2012.

operations.


Use of Non-GAAP Financial Measures

In order to provide investors with greater insight, and allow for a more comprehensive understanding of the information used by management and the board of directors in its financial and operational decision-making, wethe Company may supplement the Condensed Consolidated Financial Statements presented on a GAAP basis in this quarterly report on Form 10-Q with the following non-GAAP financial measures: EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted EBITDA Margin.

per diluted share.


21

Index to Financial Statements

These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of ourCompany results as reported under GAAP. We compensateThe Company compensates for such limitations by relying primarily on our GAAP results and using non-GAAP financial measures only as supplemental data. We also provide a reconciliation of non-GAAP to GAAP measures used. Investors are encouraged to carefully review this reconciliation. In addition, because these non-GAAP measures are not measures of financial performance under GAAP and are susceptible to varying calculations, these measures, as defined by us,the Company, may differ from and may not be comparable to similarly titled measures used by other companies.

EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted EBITDA per diluted share

We define:

The Company defines: (i) EBITDA, as net incomeearnings (loss) before net interest expense, income tax expense (benefit), depreciation and amortization; (ii) Adjusted EBITDA, as net incomeearnings (loss) before net interest expense, income tax expense (benefit), depreciation, amortization, non-recurringstock-based compensation expense, and transaction expenses and stock-based compensation expense;other one-time costs; (iii) Adjusted EBITDA Margin, as Adjusted EBITDA as a percentage of net revenue; and (iv) Adjusted EBITDA per diluted share as Adjusted EBITDA divided by adjusted diluted shares outstanding. EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted EBITDA per diluted share are used to facilitate a comparison of our operating performance on a consistent basis from period to period and provide for a more complete understanding of factors and trends affecting our business than GAAP measures alone. These measures assist management and the board and may be useful to investors in comparing ourthe Company’s operating performance consistently over time as they remove the impact of our capital structure (primarily interest charges), asset base (primarily depreciation and amortization) and, items outside the control of the management team (taxes). Adjusted EBITDA removes the impact of, and costs that we expect to be non-recurring including: transaction related expenses (such as professional and advisory services), corporate restructuring expenses (such as severances), and other operating costs that are not expected to be recurring in the normal course of our business.non-recurring. Adjusted EBITDA removes the impact of share-based compensation expense, which is another non-cash item outside of management’s control.item. Adjusted EBITDA per diluted share will include incremental shares in the share count that would be considered anti-dilutive in a GAAP net loss position.

The board of directors and management also use these measures as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating, on at least a quarterly and annual basis, actual results against such expectations; and, (ii) as a performance evaluation metric in determining achievement of certain executive and associate incentive compensation programs.

Our

The Company’s lenders use a variation of Adjusted EBITDA to assess our operating performance. OurThe Company’s credit agreements with ourits lender require delivery of compliance reports certifying compliance with financial covenants certain of which are based on an adjusted EBITDA measurement that is similar tothe same as the Adjusted EBITDA measurement reviewed by our management and board of directors.

EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin are not measures of liquidity under GAAP, or otherwise, and are not alternatives to cash flow from continuing operating activities; despite the advantages regarding the use and analysis of these measures

as mentioned above. EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted EBITDA per diluted share as disclosed in this quarterly report on Form 10-Q, have limitations as analytical tools, and you should not consider these measures in isolation, or as a substitute for analysis of ourCompany results as reported under GAAP; nor are these measures intended to be measures of liquidity or free cash flow for our discretionary use. Some of the limitations of EBITDA, and its variations are:

EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments;

EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

EBITDA does not reflect the interest expense, or the cash requirements to service interest or principal payments under our credit agreement;

EBITDA does not reflect income tax payments we are required to make; and

Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized often will have to be replaced in the future, and EBITDA does not reflect any cash requirements for such replacements.

Adjusted EBITDA has all the inherent limitations of EBITDA. To properly and prudently evaluate our business, we encouragethe Company encourages readers to review the GAAP financial statements included elsewhere in this quarterly report on Form 10-Q, and not rely on any single financial measure to evaluate our business. WeThe Company also strongly urgeurges readers to review the reconciliation of GAAP net earnings (loss) to Adjusted EBITDA, and GAAP earnings (loss) per diluted share to Adjusted EBITDA per diluted share in this section, along with the Condensed Consolidated Statement of OperationsFinancial Statements included elsewhere in this quarterly report on Form 10-Q.


22

Index to Financial Statements

The following table sets forth a reconciliation of EBITDA and Adjusted EBITDA to net income,earnings (loss), a comparable GAAP-based measure, as well as earnings (loss) per diluted share to Adjusted EBITDA per diluted share. All of the items included in the reconciliation from net earnings (loss) to EBITDA to Adjusted EBITDA and the related per share calculations are either (i) recurring non-cash items, or items that management does not consider in assessing ourthe Company’s on-going operating performance. In the case of the non-cash items, management believes that investors may find it useful to assess ourthe Company’s comparative operating performance because the measures without such items are less susceptible to variances in actual performance resulting from depreciation, amortization and other non-cash chargesnon-recurring expenses and more reflective of other factors that affect operating performance. In the case of the other non-recurring items, management believes that investors may find it useful to assess ourthe Company’s operating performance if the measures are presented without these items because their financial impact does not reflect ongoing operating performance.

The following table reconciles net earnings (loss) to EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted EBITDA per diluted share for the threefiscal periods ended April 30, 2013 and nine months ended October 31, 2012 and 2011 (amounts in thousands, except per share data):

   Three Months Ended,   Nine Months Ended, 
   October 31,
2012
  October 31,
2011
   October 31,
2012
  October 31,
2011
 

Adjusted EBITDA Reconciliation

      

Net earnings

  $2,400   $296    $2,428   $8  

Interest expense

   895    26     1,494    68  

Income tax expense

   (3,553  5     (3,520  12  

Depreciation

   184    163     548    553  

Amortization of capitalized software development costs

   708    454     1,930    1,455  

Amortization of intangible assets

   229    —       254    —    
  

 

 

  

 

 

   

 

 

  

 

 

 

EBITDA

   863    944     3,134    2,096  
  

 

 

  

 

 

   

 

 

  

 

 

 

Stock-based compensation expense

   245    133     645    529  

Transaction expenses

   494    —       1,043    —    
  

 

 

  

 

 

   

 

 

  

 

 

 

Adjusted EBITDA

  $1,602   $1,077    $4,822   $2,625  
  

 

 

  

 

 

   

 

 

  

 

 

 

Adjusted EBITDA per diluted share

      

Earnings per share - diluted

  $0.15   $0.03    $0.18   $0.00  
  

 

 

  

 

 

   

 

 

  

 

 

 

Adjusted EBITDA per diluted share

  $0.10   $0.11    $0.39   $0.27  
  

 

 

  

 

 

   

 

 

  

 

 

 

Diluted weighted average shares

   15,365,238    9,958,947     12,417,256    9,837,750  


 Three Months Ended
Adjusted EBITDA ReconciliationApril 30, 2013 April 30, 2012
Net earnings (loss)$(2,710) $492
Interest expense567
 208
Tax expenses20
 9
Depreciation171
 180
Amortization of capitalized software development costs695
 555
Amortization of intangible assets314
 91
     Amortization of other costs10
 
EBITDA(933) 1,535
Stock-based compensation expense467
 178
Associate severances and other costs relating to transactions or corporate restructuring383
 
Non-cash valuation adjustments to assets and liabilities645
 
Transaction related professional fees, advisory fees, and other internal direct costs74
 
Other non-recurring operating expenses49
 
Adjusted EBITDA$685
 $1,713
Adjusted EBITDA margin(1)11% 31%
    
Adjusted EBITDA per diluted shareApril 30, 2013 April 30, 2012
Earnings (loss) per share — diluted$(0.24) $0.05
Adjusted EBITDA per adjusted diluted share (2)$0.04
 $0.17
Diluted weighted average shares12,534,474
 10,337,109
Includable incremental shares — adjusted EBITDA(3)5,213,514
 
Adjusted diluted shares17,747,988
 10,337,109
_______________
(1)Adjusted EBITDA as a percentage of GAAP revenues
(2)Adjusted EBITDA per adjusted diluted share for the Company's common stock is computed using the more dilutive of the two-class method or the if-converted method
(3)The number of incremental shares that would be dilutive under profit assumption, only applicable under a GAAP net loss. If GAAP profit is earned in the current period, no additional incremental shares are assumed
Application of Critical Accounting Policies
The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Management considers an accounting policy to be critical if the accounting policy requires management to make particularly difficult, subjective or complex judgments about matters that are inherently uncertain. A summary of our critical accounting policies is included in ITEM 7. Management’s Discussion And Analysis Of Financial Condition And Results Of Operations, of Part II, of our Annual

23

Index to Financial Statements

Report on Form 10-K for the fiscal year ended January 31, 2013. There have been no material changes to the critical accounting policies disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2013.
Liquidity and Capital Resources

Our

The Company’s liquidity is dependent upon numerous factors including: (i) the timing and amount of revenues and collection of contractual amounts from clients, (ii) amounts invested in research and development, capital expenditures, and (iii) the level of operating expenses, all of which can vary significantly from quarter-to-quarter. OurThe Company’s primary cash requirements include regular payment of payroll and other business expenses, interest payments on debt, and capital expenditures. Capital expenditures generally include computer hardware and computer software to support internal development efforts or infrastructure in the SaaS data center. Operations are funded by cash generated by operations and borrowings under credit facilities. We believeThe Company believes that the cash flows from operations and available credit facilities are adequate to fund our current obligations for the next twelve months. Cash and cash equivalents balances at October 31, 2012April 30, 2013 and January 31, 20122013 were $10,529,000$4,001,000 and $2,243,000,$7,500,000 , respectively. Continued expansion may require usthe Company to take on additional debt, or raise capital through issuance of equities, or a combination of both. There can be no assurance that wethe Company will be able to raise the capital required to fund further expansion.

Significant cash obligations

(in thousands)As of April 30
2013 2012
Term loans$13,375
 $13,688
Contingent consideration for earn-out (1)1,320
 1,320
Capital leases (2)
 
_______________
(1)Estimated for financial disclosure purposes only. Please reference “Note F – Debt” in the Notes to the Condensed Consolidated Financial Statements for additional information.
(2)We entered into a capital lease for computer equipment that will commence in the second quarter of fiscal 2013. The lease is for a 24-month period and we will be obligated to pay approximately $298,000 over that period.
In December 2011, the Company signed a definitive asset purchase agreement to purchase substantially all of Interpoint’s assets for a combination of cash and a convertible subordinated note totaling $5,000,000. Additionally, the Agreement provided for a contingent earn out payment in cash or convertible subordinated notes based on Interpoint’s financial performance for the twelve month period beginning six months after closing and ending 12 months thereafter. Please reference “Note F—Debt” in the Notes to the Condensed Consolidated Financial Statements for additional information.
In conjunction with the Meta acquisition, on August 16, 2012, we amended our previous term loan and line of credit agreements with Fifth Third Bank, whereby Fifth Third Bank provided us with a $5,000,000 revolving line of credit, a $5,000,000 senior term loan and a $9,000,000 subordinated term loan, a portion of which was used to refinance the previously outstanding $4,120,000 subordinated term loan. Please reference a Note F—Debt” in the Notes to the Condensed Consolidated Financial Statements for additional information.
Operating Cash Flow Activities

   Nine months ended October 31, 
(in thousands)  2012  2011 

Net income (loss)

  $2,428   $8  

Non-cash adjustments to income

   184    2,604  

Cash impact of changes in assets and liabilities

   (143  (1,986
  

 

 

  

 

 

 

Operating cash flow

  $2,469   $626  
  

 

 

  

 

 

 

cash flow activities


(in thousands)Three Months Ended
April 30, 2013 April 30, 2012
Net earnings (loss)$(2,710) $492
Non-cash adjustments to net earnings (loss)2,376
 1,024
Cash impact of changes in assets and liabilities(2,375) 110
Operating cash flow$(2,709) $1,626

Net cash (used in) provided by operating activities for the nine months ended October 31, 2012 increasedin fiscal 2013 decreased in the current year primarily due to oura decrease in profitability, decreases in accounts payable, as well as an increase in accounts receivablereceivables. This was offset primarily by non-cash adjustmentsincreases from increased depreciation andincreases in amortization expense of property and equipment, amortization ofexpenses from capitalized software development costs intangibles amortization and debt discount amortization. This was partially offset by a decrease in profitability andintangible assets, increased share based compensation expense, an increase to the warrant liability, and a reduction in deferred revenues which were recognized out of backlog.

Ourrevenue.

The Company’s clients typically have been well-established hospitals or medical facilities or major health information system companies that resell ourthe Company’s solutions, which have good credit histories and payments have been received

24

Index to Financial Statements

within normal time frames for the industry. However, some healthcare organizations have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental entities. Agreements with clients often involve significant amounts and contract terms typically require clients to make progress payments. Adverse economic events, as well as uncertainty in the credit markets, may adversely affect the availability of financing for some of our clients.

Investing Cash Flow Activities

   Nine months ended October 31, 
(in thousands)  2012  2011 

Purchases of property and equipment

  $(546 $(245

Capitalized software development costs

   (1,571  (1,970

Payment for acquisition

   (12,162  —    
  

 

 

  

 

 

 

Investing cash flow

  $(14,279 $(2,215
  

 

 

  

 

 

 

cash flow activities


(in thousands)Three Months Ended
April 30, 2013 April 30, 2012
Purchases of property and equipment$(79) $(228)
Capitalized software development costs(460) (507)
Investing cash flow$(539) $(735)

The use ofdecrease in cash used for investing cash flowsactivities is primarily attributable toa result of a reduction in the acquisition of Meta in August of 2012,hours available for capitalization as well as capitalization of software development costs. We estimatea decrease in capital expenditures as compared to the prior comparable quarter. The Company estimates that replicating ourto replicate its existing internally developed software would cost significantly more than the stated net book value.value of $12,582,000, including acquired internally developed software of Meta and Interpoint, at April 30, 2013. Many of the programs related to capitalized software development continue to have significant value to ourthe Company’s current solutions and those under development, as the concepts, ideas, and software code are readily transferable and are incorporated into new solutions.

Financing cash flow activities

   Nine months ended October 31, 
(in thousands)  2012  2011 

Net change in borrowings

  $9,880   $550  

Proceeds from exercise of stock options, stock purchase plan, and subscriptions

   162    93  

Payment of deferred financing costs

   (1,246  —    

Proceeds from private placement

   12,000    —    

Payment of success fees

   (700  —    

Payments on capital lease obligation

   —      (157
  

 

 

  

 

 

 

Financing cash flow

  $20,096   $486  
  

 

 

  

 

 

 


(in thousands)Three Months Ended
April 30, 2013 April 30, 2012
Principal repayments on term loans$(313) $
Other62
 
Financing cash flow$(251) $

The increasedecrease in cash provided byfrom financing activities was primarily the result of the private placement financing that we completed in August 2012, as well as the increase inrepayments on the term loan borrowings.

loans.


25

Index to Financial Statements

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

Item 4.   CONTROLS AND PROCEDURES

As of the end of the period covered by this quarterly report on Form 10-Q, an evaluation was performed under the supervision and with the participation of our senior management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures to provide reasonable assurance of achieving the desired objectives of the disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our management, including ourthe Chief Executive Officer and Chief Financial Officer, concluded that there is reasonable assurance that our disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this quarterly report on Form 10-Q.

There The Company's policies and procedures did not provide for a sufficiently detailed review of contract terms. As a result, a few instances were identified during the current quarter related to the inaccurate application of U.S. generally accepted accounting principles (GAAP) with respect to certain contract terms. Following completion of the quarter, we strengthened the depth of our internal financial team with the addition of a Chief Accounting Officer with significant industry and accounting experience. In addition, we performed additional analysis and other post-closing procedures to ensure that our consolidated financial statements were prepared in accordance with GAAP. Accordingly, we believe that the consolidated financial statements included in this report fairly present, in all material respects, our financial condition, results of operations, and cash flows for the periods presented.

Except as described above, there were no material changes in our internal controls over financial reporting during the three months ended October 31, 2012most recently completed fiscal quarter that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.




26

Part



PART II. OTHER INFORMATION


Item 1.LEGAL PROCEEDINGS

We are, from time to time, a party to various legal proceedings and claims, which arise, in the ordinary course of business. We are not aware of any legal matters that will have a material adverse effect on our consolidated results of operations or consolidated financial position and cash flows.

Item 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On October 19, 2012, we issued 200,000 warrants to our placement agent as a portion of the fees for services rendered in the private placement investment. The warrants have an initial exercise date of May 1, 2013 and are exercisable for a five year term thereafter at a stated exercise price of $4.06 per share and could be exercised in whole or in part of any time. The warrants also included a cashless exercise option which allowed the holder to receive a number of shares of common stock based on an agreed formula in exchange for the warrants rather than paying cash to exercise. The warrants have no reset provisions.

Item 6.EXHIBITS

See Index to Exhibits.




27


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrantRegistrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


STREAMLINE HEALTH

SOLUTIONS, INC.

DATE: December 14, 2012By:

/s/ Robert E. Watson

Robert E. Watson

Chief Executive Officer

DATE: December 14, 2012By:

/s/ Stephen H. Murdock

Stephen H. Murdock

Chief Financial Officer

INDEX TO EXHIBITS

Exhibit

No.


 

Description of Exhibit

STREAMLINE HEALTH SOLUTIONS, INC.
DATE: June 14, 2013By:
/S/    Robert E. Watson

Robert E. Watson
Chief Executive Officer
DATE: June 14, 2013By:
/S/    Nicholas A. Meeks
Nicholas A. Meeks
Chief Financial Officer



28

Index to Financial Statements

INDEX TO EXHIBITS
EXHIBITS

  31.1Exhibit No.Description of Exhibit
3.1(a)Certificate of Incorporation of Streamline Health Solutions, Inc. f/k/a/ LanVision Systems, Inc. (Incorporated herein by reference from the Registration Statement on Form S-1, File Number 333-01494, as filed with the Commission on April 15, 1996.)
3.1(b)Certificate of Incorporation of Streamline Health Solutions, Inc., amendment No. 1. (Incorporated herein by reference from Exhibit 3.1(b) of the Form 10-Q, as filed with the Commission on September 8, 2006.)
3.2Bylaws of Streamline Health Solutions, Inc., as amended and restated on July 22, 2010, (Incorporated herein by reference from Exhibit 3.2 of Form 10-Q, as filed with the Commission on September 9, 2010.)
3.3Certificate of the Designations, Powers, Preferences and Rights of the Convertible Preferred Stock (Par Value $.01 Per Share) of Streamline Health Solutions, Inc. (Incorporated herein by reference from the Registration Statement on Form S-1, File Number 333-01494, as filed with the Commission on April 15, 1996.)
10.1#Employment Agreement dated April 22, 2013 between Streamline Health Solutions, Inc. and Robert E. Watson (Incorporated herein by reference from Exhibit 10.1 of the Form 8-K, as filed with the Commission on April 26, 2013.)
10.2#Form of Stock Option Agreement pursuant to the 2013 Stock Incentive Plan of Streamline Health Solutions, Inc.
10.3#Form of Restricted Stock Award Agreement (for Directors) pursuant to the 2013 Stock Incentive Plan of Streamline Health Solutions, Inc.
31.1***Certification by Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  31.231.2***Certification by Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  32.132.1***Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  32.232.2***Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101The following financial information from Streamline Health Solutions, Inc.'s Quarterly Report on Form 10-Q for the three month period ended April 30, 2013 filed with the SEC on June 14, 2013, formatted in XBRL includes: (i) Condensed Consolidated Balance Sheets at April 30, 2013 and January 31, 2013, (ii)Condensed Consolidated Statements of Operations for three month periods ended April 30, 2013 and 2012, (iii) Condensed Consolidated Statements of Cash Flows for the three month periods ended April 30, 2013 and 2012, and (iv) Notes to the Condensed Consolidated Financial Statements.
101.INSXBRL Instance Document


_______________

101.SCH***XBRL Taxonomy Extension Schema DocumentIncluded herein
101.CAL#XBRL Taxonomy Extension Calculation Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase DocumentManagement Contracts and Compensatory Arrangements.

26


Our SEC file number reference for documents filed with the SEC pursuant to the Securities Exchange Act of 1943, as amended, is 0-281


29